Unnamed: 0 float64 0 700k | Date stringlengths 23 23 | Article_title stringlengths 1 250 | Stock_symbol stringlengths 1 5 | Url stringlengths 44 135 | Publisher float64 | Author float64 | Article stringlengths 1 343k ⌀ | Lsa_summary stringlengths 48 53.9k ⌀ | Luhn_summary stringlengths 1 53.9k ⌀ | Textrank_summary stringlengths 1 53.9k ⌀ | Lexrank_summary stringlengths 1 53.9k ⌀ |
|---|---|---|---|---|---|---|---|---|---|---|---|
25,500 | 2018-05-28 00:00:00 UTC | AbbVie (ABBV) Up 5.9% Since Earnings Report: Can It Continue? | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-up-5.9-since-earnings-report%3A-can-it-continue-2018-05-28 | null | null | A month has gone by since the last earnings report for AbbVie Inc.ABBV . Shares have added about 5.9% in that time frame.
Will the recent positive trend continue leading up to its next earnings release, or is ABBV due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a q... | A month has gone by since the last earnings report for AbbVie Inc.ABBV . Will the recent positive trend continue leading up to its next earnings release, or is ABBV due for a pullback? AbbVie Tops Q1 Earnings & Revenue Estimates, Ups 2018 Guidance AbbVie reported better-than-expected earnings and sales for the first qu... | AbbVie Inc. Price and Consensus AbbVie Inc. Price and Consensus | AbbVie Inc. Quote VGM Scores At this time, ABBV has a nice Growth Score of B, however its Momentum is doing a bit better with an A. A month has gone by since the last earnings report for AbbVie Inc.ABBV . Will the recent positive trend continue leading u... | A month has gone by since the last earnings report for AbbVie Inc.ABBV . Will the recent positive trend continue leading up to its next earnings release, or is ABBV due for a pullback? AbbVie Tops Q1 Earnings & Revenue Estimates, Ups 2018 Guidance AbbVie reported better-than-expected earnings and sales for the first qu... | AbbVie Tops Q1 Earnings & Revenue Estimates, Ups 2018 Guidance AbbVie reported better-than-expected earnings and sales for the first quarter of 2018. Previously, AbbVie expected operating margin to be approximately 44% of sales. A month has gone by since the last earnings report for AbbVie Inc.ABBV . |
25,501 | 2018-05-25 00:00:00 UTC | After Hours Most Active for May 25, 2018 : ABBV, KR, QQQ, IBM, V, CPE, LOW, SBUX, QCOM, TXN, CELG, INTC | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-may-25-2018-abbv-kr-qqq-ibm-v-cpe-low-sbux-qcom-txn-celg-intc-2018 | null | null | The NASDAQ 100 After Hours Indicator is down -2.59 to 6,958.33. The total After hours volume is currently 19,826,015 shares traded.
The following are the most active stocks for the after hours session :
AbbVie Inc. ( ABBV ) is unchanged at $101.08, with 4,304,722 shares traded. Over the last four weeks they have had 6 ... | The following are the most active stocks for the after hours session : AbbVie Inc. ( ABBV ) is unchanged at $101.08, with 4,304,722 shares traded. ABBV's current last sale is 89.45% of the target price of $113. International Business Machines Corporation ( IBM ) is unchanged at $143.64, with 1,201,972 shares traded. | The following are the most active stocks for the after hours session : AbbVie Inc. ( ABBV ) is unchanged at $101.08, with 4,304,722 shares traded. ABBV's current last sale is 89.45% of the target price of $113. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter endin... | The following are the most active stocks for the after hours session : AbbVie Inc. ( ABBV ) is unchanged at $101.08, with 4,304,722 shares traded. ABBV's current last sale is 89.45% of the target price of $113. Over the last four weeks they have had 6 up revisions for the earnings forecast, for the fiscal quarter endin... | The following are the most active stocks for the after hours session : AbbVie Inc. ( ABBV ) is unchanged at $101.08, with 4,304,722 shares traded. ABBV's current last sale is 89.45% of the target price of $113. Visa Inc. ( V ) is +0.2 at $131.48, with 1,175,332 shares traded. |
25,502 | 2018-05-23 00:00:00 UTC | Analysts Expect 10% Gains Ahead For The Holdings of FTHI | ABBV | https://www.nasdaq.com/articles/analysts-expect-10-gains-ahead-holdings-fthi-2018-05-23 | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust BuyWrite Income ET... | Below is a twelve month price history chart comparing the stock performance of GOOGL, VZ, and ABBV: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of FTHI's un... | Three of FTHI's underlying holdings with notable upside to their analyst target prices are Alphabet Inc (Symbol: GOOGL), Verizon Communications Inc (Symbol: VZ), and AbbVie Inc (Symbol: ABBV). Similarly, VZ has 14.54% upside from the recent share price of $48.81 if the average analyst target price of $55.91/share is re... | Similarly, VZ has 14.54% upside from the recent share price of $48.81 if the average analyst target price of $55.91/share is reached, and analysts on average are expecting ABBV to reach a target price of $119.38/share, which is 12.38% above the recent price of $106.23. Below is a twelve month price history chart compar... | Below is a twelve month price history chart comparing the stock performance of GOOGL, VZ, and ABBV: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of FTHI's un... |
25,503 | 2018-05-23 00:00:00 UTC | Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis | ABBV | https://www.nasdaq.com/articles/eli-lilly-gets-fda-approval-for-taltz-in-genital-psoriasis-2018-05-23 | null | null | Eli Lilly & CompanyLLY announced that the FDA has approved the inclusion of additional data on the label of its psoriasis injection, Taltz. With the latest approval, Taltz label will now include data for psoriasis involving the genital area, which impacts roughly 63% of psoriasis patients over the course of their disea... | Though many other drugs like Novartis' NVS Cosentyx, J&J's JNJ Tremfya and AbbVie's ABBV Humira are approved to treat plaque psoriasis, Lilly claims Taltz is now the first and only FDA approved treatment for genital psoriasis Taltz is also being studied in a late-stage study for axial spondyloarthritis. Click to get th... | Click to get this free report Eli Lilly and Company (LLY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Though many other drugs like Novartis' NVS ... | Though many other drugs like Novartis' NVS Cosentyx, J&J's JNJ Tremfya and AbbVie's ABBV Humira are approved to treat plaque psoriasis, Lilly claims Taltz is now the first and only FDA approved treatment for genital psoriasis Taltz is also being studied in a late-stage study for axial spondyloarthritis. Click to get th... | Though many other drugs like Novartis' NVS Cosentyx, J&J's JNJ Tremfya and AbbVie's ABBV Humira are approved to treat plaque psoriasis, Lilly claims Taltz is now the first and only FDA approved treatment for genital psoriasis Taltz is also being studied in a late-stage study for axial spondyloarthritis. Click to get th... |
25,504 | 2018-05-23 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Pfizer Inc. | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-pfizer-inc-2018-05-23 | null | null | If you're looking to buy a big pharma stock, both AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) have a lot to offer. AbbVie has been the bigger winner in recent years. The stock is up close to 130% over the past five years, while Pfizer's share price gained only 25% during the period.
But past performance doesn't count fo... | We saw some of this volatility for AbbVie in March when a clinical failure for experimental cancer drug Rova-T wiped out a big chunk of the company's market cap. If you're looking to buy a big pharma stock, both AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) have a lot to offer. AbbVie has been the bigger winner in recent ... | AbbVie uses only 42% of its free cash flow to fund the dividend, indicating plenty of flexibility for more dividend hikes in the future. Factoring in the company's projected growth gives AbbVie a PEG ratio of only 0.75 -- making this big pharma a big bargain. Pfizer uses a little over half of its free cash flow to fund... | The case for Pfizer While AbbVie relies on one drug -- Humira -- for close to 60% of its total revenue, Pfizer has a much more diversified portfolio. Pfizer uses a little over half of its free cash flow to fund the dividend, giving it similar flexibility as AbbVie in rolling out future dividend increases. If you're loo... | If you're looking to buy a big pharma stock, both AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) have a lot to offer. AbbVie has been the bigger winner in recent years. Here's how AbbVie and Pfizer compare. |
25,505 | 2018-05-23 00:00:00 UTC | After Hours Most Active for May 23, 2018 : GE, F, BAC, MSFT, ABBV, CFG, INTC, CSCO, DCUD, MDLZ, AAPL, AMAT | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-may-23-2018-ge-f-bac-msft-abbv-cfg-intc-csco-dcud-mdlz-aapl-amat | null | null | The NASDAQ 100 After Hours Indicator is down -4.68 to 6,948.95. The total After hours volume is currently 43,262,928 shares traded.
The following are the most active stocks for the after hours session :
General Electric Company ( GE ) is -0.01 at $14.17, with 5,334,570 shares traded. GE's current last sale is 76.59% of... | AbbVie Inc. ( ABBV ) is unchanged at $105.60, with 1,839,379 shares traded. ABBV's current last sale is 93.45% of the target price of $113. The following are the most active stocks for the after hours session : General Electric Company ( GE ) is -0.01 at $14.17, with 5,334,570 shares traded. | AbbVie Inc. ( ABBV ) is unchanged at $105.60, with 1,839,379 shares traded. ABBV's current last sale is 93.45% of the target price of $113. Over the last four weeks they have had 12 up revisions for the earnings forecast, for the fiscal quarter ending Jun 2018. | AbbVie Inc. ( ABBV ) is unchanged at $105.60, with 1,839,379 shares traded. ABBV's current last sale is 93.45% of the target price of $113. As reported by Zacks, the current mean recommendation for BAC is in the "buy range". | AbbVie Inc. ( ABBV ) is unchanged at $105.60, with 1,839,379 shares traded. ABBV's current last sale is 93.45% of the target price of $113. Intel Corporation ( INTC ) is unchanged at $55.21, with 1,772,742 shares traded. |
25,506 | 2018-05-22 00:00:00 UTC | Noteworthy Tuesday Option Activity: ABBV, GRA, WSM | ABBV | https://www.nasdaq.com/articles/noteworthy-tuesday-option-activity-abbv-gra-wsm-2018-05-22 | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 37,171 contracts has been traded thus far today, a contract volume which is representative of approximately 3.7 million underlying shares (given that e... | Particularly high volume was seen for the $120 strike call option expiring June 08, 2018 , with 8,500 contracts trading so far today, representing approximately 850,000 underlying shares of ABBV. Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbVie... | Particularly high volume was seen for the $120 strike call option expiring June 08, 2018 , with 8,500 contracts trading so far today, representing approximately 850,000 underlying shares of ABBV. Below is a chart showing ABBV's trailing twelve month trading history, with the $120 strike highlighted in orange: Grace & C... | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 37,171 contracts has been traded thus far today, a contract volume which is representative of approximately 3.7 million underlying shares (given that e... | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in AbbVie Inc (Symbol: ABBV), where a total volume of 37,171 contracts has been traded thus far today, a contract volume which is representative of approximately 3.7 million underlying shares (given that e... |
25,507 | 2018-05-22 00:00:00 UTC | The Zacks Analyst Blog Highlights: Procter & Gamble, AbbVie, McDonald???s and PepsiCo | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-procter-gamble-abbvie-mcdonalds-and-pepsico-2018-05-0 | null | null | For Immediate Release
Chicago, IL - May 22, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Procter & GamblePG , AbbVieABBV... | Moreover, Imbruvica has multibillion dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases. Stocks recently featured in the blog include Procter & GamblePG , AbbVieABBV , McDonald'sMCD and PepsiCoPEP . Here are highlights from Monday's Analyst Blog: Top An... | Here are highlights from Monday's Analyst Blog: Top Analyst Reports for P&G, AbbVie, McDonalds and Pepsico The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 17 major stocks, including Procter & Gamble, AbbVie, McDonald's and PepsiCo. ... | Here are highlights from Monday's Analyst Blog: Top Analyst Reports for P&G, AbbVie, McDonalds and Pepsico The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 17 major stocks, including Procter & Gamble, AbbVie, McDonald's and PepsiCo. ... | Today's Research Daily features new research reports on 17 major stocks, including Procter & Gamble, AbbVie, McDonald's and PepsiCo. Stocks recently featured in the blog include Procter & GamblePG , AbbVieABBV , McDonald'sMCD and PepsiCoPEP . Here are highlights from Monday's Analyst Blog: Top Analyst Reports for P&G, ... |
25,508 | 2018-05-22 00:00:00 UTC | Vanguard Growth ETF Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/vanguard-growth-etf-experiences-big-outflow-2018-05-22 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard Growth ETF (Symbol: VUG) where we have detected an approximate $66.7 million dollar outflow -- that's a 0.2% decrease week over week (from 232,882,000 to 232,433,141). Among the la... | Among the largest underlying components of VUG, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.2%, Comcast Corp (Symbol: CMCSA) is up about 0.7%, and Walt Disney Co. (Symbol: DIS) is higher by about 0.9%. For a complete list of holdings, visit the VUG Holdings page » The chart below shows the one year price p... | Among the largest underlying components of VUG, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.2%, Comcast Corp (Symbol: CMCSA) is up about 0.7%, and Walt Disney Co. (Symbol: DIS) is higher by about 0.9%. For a complete list of holdings, visit the VUG Holdings page » The chart below shows the one year price p... | Among the largest underlying components of VUG, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.2%, Comcast Corp (Symbol: CMCSA) is up about 0.7%, and Walt Disney Co. (Symbol: DIS) is higher by about 0.9%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Chan... | Among the largest underlying components of VUG, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.2%, Comcast Corp (Symbol: CMCSA) is up about 0.7%, and Walt Disney Co. (Symbol: DIS) is higher by about 0.9%. For a complete list of holdings, visit the VUG Holdings page » The chart below shows the one year price p... |
25,509 | 2018-05-22 00:00:00 UTC | Health Care Sector Update for 05/22/2018: VBIV,CTMX,RDY,BMRN | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-05222018-vbivctmxrdybmrn-2018-05-22 | null | null | Top Health Care Stocks
JNJ -0.74%
PFE -0.18%
ABT -1.23%
MRK -0.19%
AMGN +0.99%
Health care stocks were ending moderately lower today after giving back narrow gains earlier in the session. At last look, the NYSE Health Care Index was falling slightly almost 0.3% in recent trade. Also today, shares of health care compani... | CytomX is co-developing CX-2029 with AbbVie ( ABBV ) and this week's approval by the U.S. Food and Drug Admnistration of the company's investigational new drug application triggers a $25 million milestone payment to CytomX from Abbvie. In other sector news: + CytomX Therapeutics ( CTMX ) advanced Tuesday, at one point ... | CytomX is co-developing CX-2029 with AbbVie ( ABBV ) and this week's approval by the U.S. Food and Drug Admnistration of the company's investigational new drug application triggers a $25 million milestone payment to CytomX from Abbvie. Health care stocks were ending moderately lower today after giving back narrow gains... | CytomX is co-developing CX-2029 with AbbVie ( ABBV ) and this week's approval by the U.S. Food and Drug Admnistration of the company's investigational new drug application triggers a $25 million milestone payment to CytomX from Abbvie. Also today, shares of health care companies in the S&P 500 were down slightly more t... | CytomX is co-developing CX-2029 with AbbVie ( ABBV ) and this week's approval by the U.S. Food and Drug Admnistration of the company's investigational new drug application triggers a $25 million milestone payment to CytomX from Abbvie. Top Health Care Stocks Health care stocks were ending moderately lower today after g... |
25,510 | 2018-05-22 00:00:00 UTC | Health Care Sector Update for 05/22/2018: CTMX,RDY | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-05222018-ctmxrdy-2018-05-22 | null | null | Top Health Care Stocks
JNJ -0.68%
PFE +0.29%
ABT -1.03%
MRK +0.34%
AMGN +1.54%
Health care stocks were little changed Tuesday after giving back narrow gains earlier in the session. The NYSE Health Care Index was falling slightly more than 0.1% in recent trading. Shares of health care companies in the S&P 500 were up sl... | CytomX is co-developing CX-2029 with AbbVie ( ABBV ) and this week's approval by the US Food and Drug Admnistration of the company's investigational new drug application triggers a $25 million milestone payment to CytomX from Abbvie. Health care stocks were little changed Tuesday after giving back narrow gains earlier ... | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. CytomX is co-developing CX-2029 with AbbVie ( ABBV ) and this week's approval by the US Food and Drug Admnistration of the company's investigational new drug application triggers a $25 m... | CytomX is co-developing CX-2029 with AbbVie ( ABBV ) and this week's approval by the US Food and Drug Admnistration of the company's investigational new drug application triggers a $25 million milestone payment to CytomX from Abbvie. Shares of health care companies in the S&P 500 were up slightly more than 0.1% as a gr... | CytomX is co-developing CX-2029 with AbbVie ( ABBV ) and this week's approval by the US Food and Drug Admnistration of the company's investigational new drug application triggers a $25 million milestone payment to CytomX from Abbvie. Top Health Care Stocks Shares of health care companies in the S&P 500 were up slightly... |
25,511 | 2018-05-21 00:00:00 UTC | Roche (RHHBY) Announces Positive Data on Hemophilia Drug | ABBV | https://www.nasdaq.com/articles/roche-rhhby-announces-positive-data-on-hemophilia-drug-2018-05-21 | null | null | Roche RHHBY announced full results from the phase III study, HAVEN 3, evaluating haemophilia A drug Hemlibra (emicizumab).
The randomized multicenter, open-label, phase III study evaluated the efficacy, safety and pharmacokinetics of Hemlibra prophylaxis versus no prophylaxis (episodic/on-demand factor VIII treatment) ... | We note that Roche is developing Venclexta in collaboration with AbbVie ABBV . AbbVie is commercializing the drug outside the United States as well. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Re... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Roche is developing Venclexta in collab... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Roche is developing Venclexta in collab... | We note that Roche is developing Venclexta in collaboration with AbbVie ABBV . AbbVie is commercializing the drug outside the United States as well. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Re... |
25,512 | 2018-05-18 00:00:00 UTC | 5 Things AbbVie Investors Need to Know | ABBV | https://www.nasdaq.com/articles/5-things-abbvie-investors-need-know-2018-05-18 | null | null | Has the luster faded for AbbVie (NYSE: ABBV) ?
The big pharma company ranked as the best performer among its peers in 2017, with an impressive gain of 54%. AbbVie started off 2018 great as well. However, disappointing results from a phase 2 clinical study of cancer drug Rova-T caused the stock to skid.
Still, AbbVie's ... | AbbVie CEO Rick Gonzalez, CFO Bill Chase, and Chief Scientific Officer Michael Severino fielded questions about current products and key pipeline candidates at the Bank of America Merrill Lynch Health Care Conference on Wednesday. Rick Gonzalez stated that AbbVie is planning for a relatively slow initial ramp-up of sal... | The threat to Imbruvica isn't a big worry Imbruvica is a key component of AbbVie's growth strategy. The market overreacted to the Rova-T setback AbbVie's management team didn't talk much about the clinical setback for Rova-T. Has the luster faded for AbbVie (NYSE: ABBV) ? | Gonzalez noted that around 60% of the new patients that are using Calquence didn't respond to treatment by Imbruvica, so they don't present a net decline in market share for AbbVie's drug. Severino added that AbbVie responded promptly to the FDA's request for more information, and that the company's review of the data ... | Gonzalez said the HCV market pretty much boils down to a one-on-one match-up between AbbVie and Gilead Sciences . Has the luster faded for AbbVie (NYSE: ABBV) ? AbbVie started off 2018 great as well. |
25,513 | 2018-05-17 00:00:00 UTC | Bear of the Day: Scotts Miracle-Gro (SMG) | ABBV | https://www.nasdaq.com/articles/bear-day-scotts-miracle-gro-smg-2018-05-17 | null | null | Known for its popular lawn and garden care products, Scotts Miracle-Gro Co. (SMG) is one of the most recognized names in the gardening industry. Its U.S. brands include Scotts, Miracle-Gro, Ortho, and Smith & Hawken. The company's customers are wide-ranging, from home improvement centers and hardware chains to nurserie... | For investors wanting exposure to marijuana stocks, and one with more near-term potential, they should consider AbbVie (ABBV), a large cap biopharmaceutical company that has one of the first FDA approved cannabis-based drugs, Marinol, on the market. Click to get this free report Scotts Miracle-Gro Company (The) (SMG): ... | Click to get this free report Scotts Miracle-Gro Company (The) (SMG): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. For investors wanting exposure to marijuana stocks, and one with more near-term potential, they should consider AbbVie (ABBV), a l... | Click to get this free report Scotts Miracle-Gro Company (The) (SMG): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. For investors wanting exposure to marijuana stocks, and one with more near-term potential, they should consider AbbVie (ABBV), a l... | For investors wanting exposure to marijuana stocks, and one with more near-term potential, they should consider AbbVie (ABBV), a large cap biopharmaceutical company that has one of the first FDA approved cannabis-based drugs, Marinol, on the market. Click to get this free report Scotts Miracle-Gro Company (The) (SMG): ... |
25,514 | 2018-05-15 00:00:00 UTC | 3 Top Healthcare Stocks to Buy in May | ABBV | https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-may-2018-05-15 | null | null | Healthcare products tend to remain in demand no matter what is going on in the global economy. That's why the sector is a great place to hunt for high-quality investments.
So which stocks do our healthcare experts have their eye on right now? We asked these three Motley Fool investors to weigh in, and they picked AbbVi... | But the good times came to a screeching halt in late March when the company announced disappointing results for experimental lung cancer drug Rova-T. AbbVie lost all its gains made so far this year and then some. We asked these three Motley Fool investors to weigh in, and they picked AbbVie (NYSE: ABBV) , Cardinal Heal... | We asked these three Motley Fool investors to weigh in, and they picked AbbVie (NYSE: ABBV) , Cardinal Health (NYSE: CAH) , and Masimo (NASDAQ: MASI) . A big pharma stock that has it all Keith Speights (AbbVie): AbbVie was rocking along, with the stock soaring more than 50% in 2017 and up over 20% year to date in 2018.... | We asked these three Motley Fool investors to weigh in, and they picked AbbVie (NYSE: ABBV) , Cardinal Health (NYSE: CAH) , and Masimo (NASDAQ: MASI) . A big pharma stock that has it all Keith Speights (AbbVie): AbbVie was rocking along, with the stock soaring more than 50% in 2017 and up over 20% year to date in 2018.... | We asked these three Motley Fool investors to weigh in, and they picked AbbVie (NYSE: ABBV) , Cardinal Health (NYSE: CAH) , and Masimo (NASDAQ: MASI) . AbbVie's Q1 results reminded investors just how much the company has going for it even without its strong pipeline candidates. A big pharma stock that has it all Keith ... |
25,515 | 2018-05-11 00:00:00 UTC | Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally. | ABBV | https://www.nasdaq.com/articles/trump-announces-plan-reign-drug-prices-and-pharma-stocks-rally-2018-05-11 | null | null | On Friday, President Trump unveiled his much-anticipated plan to control drug prices in the U.S. During his presidential campaign, Trump had promised to take on the big drug companies and it was feared that the plan would include provisions that would hurt profits in the pharmaceutical industry.
As the president began... | Once it was clear direct negotiation wasn't on the agenda, investors snapped up shares of the biggest U.S. drug makers, including Abbvie ( ABBV ), Amgen ( AMGN ) and Merck ( MRK ), each of which finished the day 2% or more above their mid-speech lows. Click to get this free report Merck & Co., Inc. (MRK): Free Stock An... | Once it was clear direct negotiation wasn't on the agenda, investors snapped up shares of the biggest U.S. drug makers, including Abbvie ( ABBV ), Amgen ( AMGN ) and Merck ( MRK ), each of which finished the day 2% or more above their mid-speech lows. Click to get this free report Merck & Co., Inc. (MRK): Free Stock An... | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click... | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report Exelixis, Inc. (EXEL): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click... |
25,516 | 2018-05-10 00:00:00 UTC | 3 Dividend Stocks for In-the-Know Investors | ABBV | https://www.nasdaq.com/articles/3-dividend-stocks-know-investors-2018-05-10 | null | null | Finding dividend stocks that provide the right amount of growth, long-term stability, and consistent yields can be difficult. But they aren't impossible to find, if you know where to look.
To help you track down a few of these companies for your portfolio, we reached out to some Motley Fool contributors for dividend st... | And since generic biosimilars to its best-seller, Humira, aren't expected in the U.S. until 2023 , there's plenty of opportunity for investors to own AbbVie and pocket increasingly larger dividend checks. They came back with Uniti Group (NASDAQ: UNIT) , AbbVie (NYSE: ABBV) , and American Tower (NYSE: AMT) . A top incom... | They came back with Uniti Group (NASDAQ: UNIT) , AbbVie (NYSE: ABBV) , and American Tower (NYSE: AMT) . A top income stock that's in the bargain bin Todd Campbell (AbbVie): If you typically don't invest in healthcare, you might not know that shares in the biopharma giant AbbVie fell out of favor last month, following d... | They came back with Uniti Group (NASDAQ: UNIT) , AbbVie (NYSE: ABBV) , and American Tower (NYSE: AMT) . A top income stock that's in the bargain bin Todd Campbell (AbbVie): If you typically don't invest in healthcare, you might not know that shares in the biopharma giant AbbVie fell out of favor last month, following d... | They came back with Uniti Group (NASDAQ: UNIT) , AbbVie (NYSE: ABBV) , and American Tower (NYSE: AMT) . A top income stock that's in the bargain bin Todd Campbell (AbbVie): If you typically don't invest in healthcare, you might not know that shares in the biopharma giant AbbVie fell out of favor last month, following d... |
25,517 | 2018-05-04 00:00:00 UTC | Gilead Sciences, Inc. Stock Will Recover… Eventually | ABBV | https://www.nasdaq.com/articles/gilead-sciences-inc-stock-will-recover-eventually-2018-05-04 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
It appeared that Gilead Sciences, Inc. (NASDAQ: GILD ) had turned the corner earlier this year after a long slump. Just three years ago, Gilead reached a high of $120 per share at the height of its HCV treatment sales surge. Then its revenues went into decl... | Rival AbbVie Inc (NASDAQ: ABBV ) has brought its own rival HCV product, Mavyret, to market. Here's what could turn things around: First up, Gilead needs to slow the erosion in HCV sales to AbbVie and its Mavyret. Just three years ago, Gilead reached a high of $120 per share at the height of its HCV treatment sales surg... | Rival AbbVie Inc (NASDAQ: ABBV ) has brought its own rival HCV product, Mavyret, to market. Here's what could turn things around: First up, Gilead needs to slow the erosion in HCV sales to AbbVie and its Mavyret. InvestorPlace - Stock Market News, Stock Advice & Trading Tips It appeared that Gilead Sciences, Inc. (NASD... | Rival AbbVie Inc (NASDAQ: ABBV ) has brought its own rival HCV product, Mavyret, to market. Here's what could turn things around: First up, Gilead needs to slow the erosion in HCV sales to AbbVie and its Mavyret. InvestorPlace - Stock Market News, Stock Advice & Trading Tips It appeared that Gilead Sciences, Inc. (NASD... | Rival AbbVie Inc (NASDAQ: ABBV ) has brought its own rival HCV product, Mavyret, to market. Here's what could turn things around: First up, Gilead needs to slow the erosion in HCV sales to AbbVie and its Mavyret. Sure, HCV sales will continue to decline over time. |
25,518 | 2018-05-04 00:00:00 UTC | 3 Value Stocks for Income Investors | ABBV | https://www.nasdaq.com/articles/3-value-stocks-income-investors-2018-05-04 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
It's been a difficult market for value investors over the past few months. But that doesn't mean there aren't bargains to be had. And even better, these value stocks are also great dividend plays.
Several big name stocks have been on the decline as investor... | Value Stocks for Income Investors: AbbVie Inc. (ABBV) Source: Black Stripe via Wikimedia (Modified) Biotech firm AbbVie Inc. (NYSE: ABBV ) is another stock whose recent nosedive makes it a compelling long-term play for both value and income investors. After reaching highs of $125 per share in January, the ABBV stock ca... | Value Stocks for Income Investors: AbbVie Inc. (ABBV) Source: Black Stripe via Wikimedia (Modified) Biotech firm AbbVie Inc. (NYSE: ABBV ) is another stock whose recent nosedive makes it a compelling long-term play for both value and income investors. After reaching highs of $125 per share in January, the ABBV stock ca... | Value Stocks for Income Investors: AbbVie Inc. (ABBV) Source: Black Stripe via Wikimedia (Modified) Biotech firm AbbVie Inc. (NYSE: ABBV ) is another stock whose recent nosedive makes it a compelling long-term play for both value and income investors. After reaching highs of $125 per share in January, the ABBV stock ca... | After reaching highs of $125 per share in January, the ABBV stock came crashing down to just $100 per share after some bad news regarding its Rova-T drug studies. Value Stocks for Income Investors: AbbVie Inc. (ABBV) Source: Black Stripe via Wikimedia (Modified) Biotech firm AbbVie Inc. (NYSE: ABBV ) is another stock w... |
25,519 | 2018-05-04 00:00:00 UTC | Is Gilead Sciences Stock Finally a Bargain? | ABBV | https://www.nasdaq.com/articles/gilead-sciences-stock-finally-bargain-2018-05-04 | null | null | After releasing downright worrisome first-quarter results , Gilead Sciences (NASDAQ: GILD) has seen its shares drop by a noteworthy 11.7% in the past few days. The big concern is that Gilead's ailing hepatitis C franchise has yet to stabilize in the wake of newfound competition from AbbVie 's (NYSE: ABBV) Mavyret.
For ... | With AbbVie's drug just starting to gain commercial momentum, Gilead's hepatitis C franchise appears set to continue falling in the quarters ahead. The big concern is that Gilead's ailing hepatitis C franchise has yet to stabilize in the wake of newfound competition from AbbVie 's (NYSE: ABBV) Mavyret. AbbVie, a stock ... | AbbVie, a stock that had its own share of problems this year, after all, is still trading at over 11 times forward earnings, and the vast majority of Gilead's immediate peer group (large-cap biotechs) are trading at valuations well north of 13 times forward-looking earnings. The big concern is that Gilead's ailing hepa... | AbbVie, a stock that had its own share of problems this year, after all, is still trading at over 11 times forward earnings, and the vast majority of Gilead's immediate peer group (large-cap biotechs) are trading at valuations well north of 13 times forward-looking earnings. The big concern is that Gilead's ailing hepa... | The big concern is that Gilead's ailing hepatitis C franchise has yet to stabilize in the wake of newfound competition from AbbVie 's (NYSE: ABBV) Mavyret. With AbbVie's drug just starting to gain commercial momentum, Gilead's hepatitis C franchise appears set to continue falling in the quarters ahead. AbbVie, a stock ... |
25,520 | 2018-05-03 00:00:00 UTC | Did Gilead Sciences Make a Big Mistake? | ABBV | https://www.nasdaq.com/articles/did-gilead-sciences-make-big-mistake-2018-05-03 | null | null | Gilead Sciences (NASDAQ: GILD) reported its first-quarter earnings this week, and those results show that its hepatitis C drug revenue continues to slide because of new competition from AbbVie Inc. 's (NYSE: ABBV) Mavyret, which won approval in August. Was Gilead Sciences wrong to stop developing new hepatitis C treatm... | Gilead Sciences (NASDAQ: GILD) reported its first-quarter earnings this week, and those results show that its hepatitis C drug revenue continues to slide because of new competition from AbbVie Inc. 's (NYSE: ABBV) Mavyret, which won approval in August. On the company's earnings conference call last month, CEO Richard G... | AbbVie pockets Gilead's profit Unlike Gilead Sciences, AbbVie continued developing its next-generation hepatitis C drug, Mavyret, and based on its performance, it seems that was the right decision. Gilead Sciences (NASDAQ: GILD) reported its first-quarter earnings this week, and those results show that its hepatitis C ... | AbbVie pockets Gilead's profit Unlike Gilead Sciences, AbbVie continued developing its next-generation hepatitis C drug, Mavyret, and based on its performance, it seems that was the right decision. Gilead Sciences (NASDAQ: GILD) reported its first-quarter earnings this week, and those results show that its hepatitis C ... | Gilead Sciences (NASDAQ: GILD) reported its first-quarter earnings this week, and those results show that its hepatitis C drug revenue continues to slide because of new competition from AbbVie Inc. 's (NYSE: ABBV) Mavyret, which won approval in August. AbbVie pockets Gilead's profit Unlike Gilead Sciences, AbbVie conti... |
25,521 | 2018-05-02 00:00:00 UTC | Gilead (GILD) Q1 Earnings & Sales Miss Estimates on Weak HCV | ABBV | https://www.nasdaq.com/articles/gilead-gild-q1-earnings-sales-miss-estimates-on-weak-hcv-2018-05-02 | null | null | Gilead Sciences, Inc . GILD reported dismal results for the first quarter of 2018 wherein both earnings and revenues missed expectations due to a wider-than-expected decline in the hepatitis C virus (HCV) franchise.
Consequently, the stock declined in after-market hours trading and is expected to open in the red given ... | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's ABBV Viekira Pak and Viekira XR, and Merck's MRK Zepatier. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report S... | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sova... | Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report To read this article on Zacks.com click here. We note that Harvoni, Sova... | We note that Harvoni, Sovaldi and Epclusa, face competition from AbbVie's ABBV Viekira Pak and Viekira XR, and Merck's MRK Zepatier. Click to get this free report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report S... |
25,522 | 2018-05-02 00:00:00 UTC | Seattle Genetics Accelerates Revenue Growth, Earnings Not So Much | ABBV | https://www.nasdaq.com/articles/seattle-genetics-accelerates-revenue-growth-earnings-not-so-much-2018-05-02 | null | null | Seattle Genetics (NASDAQ: SGEN) posted solid revenue gains in the first quarter of the year, but it was guidance for the second quarter that had investors excited about how the biotech's lead drug, Adcetris, is finally reaching its potential.
Seattle Genetics results: The raw numbers
Data source: Seattle Genetics.
What... | Seattle Genetics' partners -- Roche , AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) -- all have drugs in late-stage development using its antibody-drug conjugate technology that could result in additional milestone payments, and hopefully royalties if the drugs are approved. The larger loss came from increases in... | Seattle Genetics' partners -- Roche , AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) -- all have drugs in late-stage development using its antibody-drug conjugate technology that could result in additional milestone payments, and hopefully royalties if the drugs are approved. But, Siegall added, the newly diagnose... | Seattle Genetics' partners -- Roche , AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) -- all have drugs in late-stage development using its antibody-drug conjugate technology that could result in additional milestone payments, and hopefully royalties if the drugs are approved. Seattle Genetics (NASDAQ: SGEN) posted... | Seattle Genetics' partners -- Roche , AbbVie (NYSE: ABBV) and GlaxoSmithKline (NYSE: GSK) -- all have drugs in late-stage development using its antibody-drug conjugate technology that could result in additional milestone payments, and hopefully royalties if the drugs are approved. Looking forward Seattle Genetics pulle... |
25,523 | 2018-05-01 00:00:00 UTC | Pre-Market Most Active for May 1, 2018 : BP, TVIX, QQQ, SNE, SHOP, AAPL, ABBV, UAA, KLXI, UA, AVXS, SQQQ | ABBV | https://www.nasdaq.com/articles/pre-market-most-active-may-1-2018-bp-tvix-qqq-sne-shop-aapl-abbv-uaa-klxi-ua-avxs-sqqq | null | null | The NASDAQ 100 Pre-Market Indicator is up 8.1 to 6,613.67. The total Pre-Market volume is currently 2,072,269 shares traded.
The following are the most active stocks for the pre-market session :
BP p.l.c. ( BP ) is +0.32 at $44.91, with 394,841 shares traded. Market Realist Reports: ExxonMobil's 1Q18 Earnings Rose but ... | Seeking Alpha Reports: Tariffs Delayed, Dollar Rising, And BP Too (Wall Street Breakfast Podcast) AbbVie Inc. ( ABBV ) is +4.63 at $101.18, with 171,018 shares traded. ABBV's current last sale is 89.54% of the target price of $113. Market Realist Reports: ExxonMobil's 1Q18 Earnings Rose but Missed Estimates Credit Suis... | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Seeking Alpha Reports: Tariffs Delayed, Dollar Rising, And BP Too (Wall Street Breakfast Podcast) AbbVie Inc. ( ABBV ) is +4.63 at $101.18, with 171,018 shares traded. ABBV's current las... | Seeking Alpha Reports: Tariffs Delayed, Dollar Rising, And BP Too (Wall Street Breakfast Podcast) AbbVie Inc. ( ABBV ) is +4.63 at $101.18, with 171,018 shares traded. ABBV's current last sale is 89.54% of the target price of $113. ( BP ) is +0.32 at $44.91, with 394,841 shares traded. | Seeking Alpha Reports: Tariffs Delayed, Dollar Rising, And BP Too (Wall Street Breakfast Podcast) AbbVie Inc. ( ABBV ) is +4.63 at $101.18, with 171,018 shares traded. ABBV's current last sale is 89.54% of the target price of $113. The NASDAQ 100 Pre-Market Indicator is up 8.1 to 6,613.67. |
25,524 | 2018-05-01 00:00:00 UTC | Why Nutrisystem, Tenet Healthcare, and AbbVie Jumped Today | ABBV | https://www.nasdaq.com/articles/why-nutrisystem-tenet-healthcare-and-abbvie-jumped-today-2018-05-01 | null | null | The stock market continued to be choppy on Tuesday, with major benchmarks moving in different directions. Weakness in the Dow Jones Industrial Average came largely from substantial price declines in some of the more heavily weighted stocks in the average, while the S&P 500 and Nasdaq Composite made gains. With key tech... | Nutrisystem (NASDAQ: NTRI) , Tenet Healthcare (NYSE: THC) , and AbbVie (NYSE: ABBV) were among the best performers on the day. AbbVie wants stock Finally, shares of AbbVie rose nearly 6%. Under the terms of the deal, shareholders may choose to offer to sell all or part of their holdings to AbbVie at a price that they s... | Nutrisystem (NASDAQ: NTRI) , Tenet Healthcare (NYSE: THC) , and AbbVie (NYSE: ABBV) were among the best performers on the day. AbbVie wants stock Finally, shares of AbbVie rose nearly 6%. Under the terms of the deal, shareholders may choose to offer to sell all or part of their holdings to AbbVie at a price that they s... | Under the terms of the deal, shareholders may choose to offer to sell all or part of their holdings to AbbVie at a price that they set within the given range, and AbbVie will then pay whatever minimum price lets them buy stock worth $7.5 billion. Nutrisystem (NASDAQ: NTRI) , Tenet Healthcare (NYSE: THC) , and AbbVie (N... | AbbVie wants stock Finally, shares of AbbVie rose nearly 6%. Nutrisystem (NASDAQ: NTRI) , Tenet Healthcare (NYSE: THC) , and AbbVie (NYSE: ABBV) were among the best performers on the day. Under the terms of the deal, shareholders may choose to offer to sell all or part of their holdings to AbbVie at a price that they s... |
25,525 | 2018-04-30 00:00:00 UTC | Drug Stocks Q1 Earnings to Watch on May 1: PFE, MRK & More | ABBV | https://www.nasdaq.com/articles/drug-stocks-q1-earnings-to-watch-on-may-1%3A-pfe-mrk-more-2018-04-30 | null | null | Per the latest Earnings Preview , the Q1 earnings season which has already crossed the half way mark is gaining strength with earnings and revenue growth on track to reach its highest level in seven years.
Total earnings for the 267 S&P 500 members that have already reported results are up 25.1% from the same period la... | Among the major large cap players that have reported results, Bristol-Myers Squibb BMY and AbbVie ABBV beat the Zacks Consensus Estimate for both earnings as well as sales. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & ... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Amgen Inc. (AMGN): Free S... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Amgen Inc. (AMGN): Free S... | Among the major large cap players that have reported results, Bristol-Myers Squibb BMY and AbbVie ABBV beat the Zacks Consensus Estimate for both earnings as well as sales. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & ... |
25,526 | 2018-04-30 00:00:00 UTC | Gilead (GILD) 1st Quarter Earnings: What to Expect | ABBV | https://www.nasdaq.com/articles/gilead-gild-1st-quarter-earnings-what-expect-2018-04-30 | null | null | Gilead Sciences (GILD) will report first quarter fiscal 2018 earnings results after Tuesday’s closing bell. With its shares falling some 14% in three months, a solid beat on both the top and bottom lines would be just what the doctor ordered.
The biopharma specialist, which develops a host of drugs for the treatment su... | However, increased competition from the likes of Merck (MRK) and AbbVie (ABBV) have pressured Gilead’s HCV revenues, resulting in declining sales in Harvoni and Sovaldi. Among other reasons, AbbVie’s competing HCV drug Viekira Pak and Merck‘s Zepatier are believed to be chipping away at Gilead’s lead. And there is a gr... | However, increased competition from the likes of Merck (MRK) and AbbVie (ABBV) have pressured Gilead’s HCV revenues, resulting in declining sales in Harvoni and Sovaldi. Among other reasons, AbbVie’s competing HCV drug Viekira Pak and Merck‘s Zepatier are believed to be chipping away at Gilead’s lead. And there is a gr... | However, increased competition from the likes of Merck (MRK) and AbbVie (ABBV) have pressured Gilead’s HCV revenues, resulting in declining sales in Harvoni and Sovaldi. Among other reasons, AbbVie’s competing HCV drug Viekira Pak and Merck‘s Zepatier are believed to be chipping away at Gilead’s lead. And there is a gr... | However, increased competition from the likes of Merck (MRK) and AbbVie (ABBV) have pressured Gilead’s HCV revenues, resulting in declining sales in Harvoni and Sovaldi. Among other reasons, AbbVie’s competing HCV drug Viekira Pak and Merck‘s Zepatier are believed to be chipping away at Gilead’s lead. And there is a gr... |
25,527 | 2018-04-30 00:00:00 UTC | The Good and the Bad News With Biogen Inc Earnings Results | ABBV | https://www.nasdaq.com/articles/the-good-and-the-bad-news-with-biogen-inc-earnings-results-2018-04-30 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Ahead of the Biogen Inc (NASDAQ: BIIB ) earnings report, BIIB stock touched a yearly low. This is a far cry from the $370 peak shares reached at the end of January 2018. Unless the market forgets about the bad news on its MS drug that followed its strong fo... | 2, both Biogen and AbbVie Inc (NYSE: ABBV ) withdrew its Zinbryta drug, which treats MS. Fortunately for Celgene Corporation (NASDAQ: CELG ), the drug does not amount to much sales. The Bad News Unfortunately, on Feb. 7, Biogen revealed its MS (multiple sclerosis) drug TYSABRI (natalizumab), which treats patients with ... | 2, both Biogen and AbbVie Inc (NYSE: ABBV ) withdrew its Zinbryta drug, which treats MS. Fortunately for Celgene Corporation (NASDAQ: CELG ), the drug does not amount to much sales. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ahead of the Biogen Inc (NASDAQ: BIIB ) earnings report, BIIB stock touched... | 2, both Biogen and AbbVie Inc (NYSE: ABBV ) withdrew its Zinbryta drug, which treats MS. Fortunately for Celgene Corporation (NASDAQ: CELG ), the drug does not amount to much sales. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ahead of the Biogen Inc (NASDAQ: BIIB ) earnings report, BIIB stock touched... | 2, both Biogen and AbbVie Inc (NYSE: ABBV ) withdrew its Zinbryta drug, which treats MS. Fortunately for Celgene Corporation (NASDAQ: CELG ), the drug does not amount to much sales. The Good News With First Quarter Results Biogen reported revenue growing 11.4%, to $3.131 billion in the first quarter. Anti-CD20 revenue ... |
25,528 | 2018-04-28 00:00:00 UTC | AbbVie's First Quarter: Can We Quit Worrying About Humira Now? | ABBV | https://www.nasdaq.com/articles/abbvies-first-quarter-can-we-quit-worrying-about-humira-now-2018-04-28 | null | null | Since AbbVie Inc. 's (NYSE: ABBV) inception, investors have been fretting about the eventual demise of its lead drug, Humira. The aging blockbuster has slowed down a bit during the first three months of the year, but the rest of the company's product lineup stepped up and delivered.
An immediate hit to Humira would sti... | AbbVie thinks upadacitinib can add around $6.5 billion to the company's top line at its peak, which looks a bit more achievable following Eli Lilly 's (NYSE: LLY) recent date at the FDA. Since AbbVie Inc. 's (NYSE: ABBV) inception, investors have been fretting about the eventual demise of its lead drug, Humira. An imme... | Since AbbVie Inc. 's (NYSE: ABBV) inception, investors have been fretting about the eventual demise of its lead drug, Humira. An immediate hit to Humira would still be devastating, but AbbVie's first quarter report suggests the company can keep the needle moving forward even if the record-breaking biologic doesn't reac... | An immediate hit to Humira would still be devastating, but AbbVie's first quarter report suggests the company can keep the needle moving forward even if the record-breaking biologic doesn't reach the lofty revenue target the company touted last year. AbbVie reported $919 billion in HCV antiviral sales, $656 million mor... | At recent prices, AbbVie's shares trade at just 12.6 times the midpoint of the company's new earnings prediction for the year. Since AbbVie Inc. 's (NYSE: ABBV) inception, investors have been fretting about the eventual demise of its lead drug, Humira. An immediate hit to Humira would still be devastating, but AbbVie's... |
25,529 | 2018-04-27 00:00:00 UTC | 3 Things You Need to Know About AbbVie's Monster Q1 Earnings | ABBV | https://www.nasdaq.com/articles/3-things-you-need-know-about-abbvies-monster-q1-earnings-2018-04-27 | null | null | AbbVie (NYSE: ABBV) ended 2017 with a bang, posting tremendous fourth-quarter results in January. The company has started 2018 with a bang, too.
On Thursday, AbbVie announced its Q1 earnings results. Wall Street analysts thought the company would report revenue of $7.6 billion. AbbVie's actual revenue total was $7.9 bi... | After Mavyret won FDA approval in August 2017, AbbVie began combining sales for both HCV drugs in its financial reports. AbbVie (NYSE: ABBV) ended 2017 with a bang, posting tremendous fourth-quarter results in January. On Thursday, AbbVie announced its Q1 earnings results. | Humira still wears the crown for now Although Mavyret and Imbruvica generated the most sizzling growth in Q1, Humira still wears the crown as the top-selling drug for AbbVie. AbbVie (NYSE: ABBV) ended 2017 with a bang, posting tremendous fourth-quarter results in January. On Thursday, AbbVie announced its Q1 earnings r... | While AbbVie shares profits on international sales with Johnson & Johnson , Imbruvica appears set to be a growth driver for AbbVie for a long time to come. Humira still wears the crown for now Although Mavyret and Imbruvica generated the most sizzling growth in Q1, Humira still wears the crown as the top-selling drug f... | However, AbbVie makes nearly 64% of total sales of Humira in the U.S. Also, the company will receive royalties on sales of the Humira biosimilars. I continue to view AbbVie as one of the more attractive pharma stocks on the market. AbbVie (NYSE: ABBV) ended 2017 with a bang, posting tremendous fourth-quarter results in... |
25,530 | 2018-04-27 00:00:00 UTC | HIV Segment to Aid Gilead (GILD) Beat Q1 Earnings Estimates? | ABBV | https://www.nasdaq.com/articles/hiv-segment-to-aid-gilead-gild-beat-q1-earnings-estimates-2018-04-27 | null | null | Biotech bigwig Gilead Sciences Inc . GILD develops drugs for the treatment of human immunodeficiency virus ("HIV"), liver diseases such as chronic hepatitis C virus ("HCV") infection and chronic hepatitis B virus ("HBV") infection, cardiovascular, hematology/oncology and inflammation/respiratory diseases.
The HCV franc... | Harvoni and Sovaldi have been facing competition from AbbVie's ABBV Viekira Pak and Merck's MRK Zepatier, among others. Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, ... | Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni and Sovaldi have been faci... | Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni and Sovaldi have been faci... | Harvoni and Sovaldi have been facing competition from AbbVie's ABBV Viekira Pak and Merck's MRK Zepatier, among others. Click to get this free report GlaxoSmithKline plc (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Gilead Sciences, ... |
25,531 | 2018-04-26 00:00:00 UTC | AbbVie (ABBV) Q1 Earnings Beat, 2018 View Up, Stock Gains | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-q1-earnings-beat-2018-view-up-stock-gains-2018-04-26 | null | null | AbbVie Inc. ABBV posted impressive results in the first quarter of 2018 with better-than-expected earnings and revenues. Moreover, the company raised its expectations for 2018 bottom line. In response, shares too climbed almost 2.5% in pre-market trading .
Shares of AbbVie have surged 42.8% in a year's time, significan... | Notably, in first-quarter earnings, AbbVie announced its intention to commence a tender offer to purchase shares of its common stock for a cash value up to $7.5 billion. AbbVie Inc. ABBV posted impressive results in the first quarter of 2018 with better-than-expected earnings and revenues. Shares of AbbVie have surged ... | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie carries a Zacks Rank #3 (Hold). Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Ligand Pharmaceut... | AbbVie Inc. Price, Consensus and EPS Surprise AbbVie Inc. Price, Consensus and EPS Surprise | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie carries a Zacks Rank #3 (Hold). Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Ligand Pharmaceut... | AbbVie Inc. ABBV posted impressive results in the first quarter of 2018 with better-than-expected earnings and revenues. Shares of AbbVie have surged 42.8% in a year's time, significantly outperforming the industry 's 3.7% rise. AbbVie logged $138 million of international profit sharing with Johnson & Johnson JNJ . |
25,532 | 2018-04-26 00:00:00 UTC | Earnings Reaction History: AbbVie Inc., 54.5% Follow-Through Indicator, 4.4% Sensitive | ABBV | https://www.nasdaq.com/articles/earnings-reaction-history-abbvie-inc-545-follow-through-indicator-44-sensitive-2018-04-26 | null | null | Expected Earnings Release: 04/26/2018, Premarket
Avg. Extended-Hours Dollar Volume: $7,003,351
AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Given its history, traders can expect very active trading in the issue immediately following its quarterly earnings an... | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 83.3% Average next regular session additional gain: 3.5% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 83.3% of... | Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of limited value in forecasting additional price movement by the following regular session close. Last 12 Qtrs Positive Only Price Reactions Percent of time added to... | Last 12 Qtrs Positive Only Price Reactions Percent of time added to extended-hours gains: 83.3% Average next regular session additional gain: 3.5% Over the prior three fiscal years (12 quarters), when shares of ABBV rose in the extended-hours session in reaction to its earnings announcement, history shows that 83.3% of... | Extended-Hours Dollar Volume: $7,003,351 AbbVie Inc. ( ABBV ) is due to issue its quarterly earnings report in the upcoming extended-hours session. Historical earnings event related premarket and after-hours trading activity in ABBV indicates that the price change in the extended hours is likely to be of limited value ... |
25,533 | 2018-04-26 00:00:00 UTC | Health Care Sector Update for 04/26/2018: ALXN,AXSM,ABBV,BMY | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-04262018-alxnaxsmabbvbmy-2018-04-26 | null | null | Top Health Care Stocks
JNJ +1.23%
PFE +0.57%
ABT +0.63%
MRK -0.29%
AMGN +0.46%
Health care stocks were mostly higher today, including a more than 1.0% gain for the NYSE Health Care Index in recent trade. Also today, shares of health care companies in the S&P 500 also were up over 1.2% as a group while the Nasdaq Biotec... | + AbbVie ( ABBV ) rose almost 6% on Thursday, topping out at $97.30 a share, after posting Q1 adjusted net income and revenue beating Wall Street expectations. The advance also was finding support from strong forward guidance and Alexion reporting positive topline data from Phase III testing of its ALXN1210 drug candia... | + AbbVie ( ABBV ) rose almost 6% on Thursday, topping out at $97.30 a share, after posting Q1 adjusted net income and revenue beating Wall Street expectations. Among health care stocks moving on news: + Alexion Pharmaceuticals ( ALXN ) was more than 12% higher in late Wednesday trading, slipping less than 10 cents off ... | + AbbVie ( ABBV ) rose almost 6% on Thursday, topping out at $97.30 a share, after posting Q1 adjusted net income and revenue beating Wall Street expectations. Among health care stocks moving on news: + Alexion Pharmaceuticals ( ALXN ) was more than 12% higher in late Wednesday trading, slipping less than 10 cents off ... | + AbbVie ( ABBV ) rose almost 6% on Thursday, topping out at $97.30 a share, after posting Q1 adjusted net income and revenue beating Wall Street expectations. Among health care stocks moving on news: + Alexion Pharmaceuticals ( ALXN ) was more than 12% higher in late Wednesday trading, slipping less than 10 cents off ... |
25,534 | 2018-04-26 00:00:00 UTC | Is a Beat in the Cards for Gilead (GILD) in Q1 Earnings? | ABBV | https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-gilead-gild-in-q1-earnings-2018-04-26 | null | null | Gilead Sciences Inc . GILD is scheduled to report first-quarter results on May 1, after the market closes .
Gilead Sciences, Inc. Price, Consensus and EPS Surprise
Gilead Sciences, Inc. Price, Consensus and EPS Surprise | Gilead Sciences, Inc. Quote
Gilead, a leader in the hepatitis C virus ("HCV") space, has a decent ... | Harvoni and Sovaldi has been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR among others. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni and Sovaldi has bee... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation (CELG): Free Stock Analysis Report To read this article on Zacks.com click here. Harvoni and Sovaldi has bee... | Harvoni and Sovaldi has been facing competition from AbbVie's ABBV Viekira Pak and Viekira XR among others. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report Celgene Corporation ... |
25,535 | 2018-04-26 00:00:00 UTC | AbbVie (ABBV) Tops Q1 Earnings and Revenues, View Up | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-tops-q1-earnings-and-revenues-view-2018-04-26 | null | null | North Chicago, IL-based AbbVie Inc. ABBV is best known for its autoimmune disease drug, Humira. AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, acti... | AbbVie's performance has been impressive, with the pharmaceuticals company delivering positive surprises in all of the past four quarter. North Chicago, IL-based AbbVie Inc. ABBV is best known for its autoimmune disease drug, Humira. AbbVie's flagship product Humira is approved for several indications like rheumatoid a... | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to... | AbbVie's flagship product Humira is approved for several indications like rheumatoid arthritis (moderate to severe), moderately to severely active polyarticular juvenile idiopathic arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease (moderate to severe), ulcerative colitis (moderate to... | Currently, AbbVie has a Zacks Rank #3 (Hold), but that could definitely change following the company's earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below: Earnings: AbbVie's first-quarter earnings came in at $1.87 per share, beating the Zacks Co... |
25,536 | 2018-04-26 00:00:00 UTC | AbbVie Inc Stock Up on Strong Earnings, Guidance Update | ABBV | https://www.nasdaq.com/articles/abbvie-inc-stock-strong-earnings-guidance-update-2018-04-26 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie Inc (NYSE: ABBV ) stock was up today following the release of its earnings report for the first quarter of the year.
Source: Black Stripe via Wikimedia (Modified)
During the first quarter of 2018, AbbVie Inc reported earnings per share of $1.89. This... | It also beat out Wall Street's earnings per share estimate of $1.79 for the quarter and was good news for ABBV stock. 7 Stocks on a Long-Term Uptrend AbbVie Inc's most recent earnings report also includes an update to its guidance for 2018. Compare Brokers The post AbbVie Inc Stock Up on Strong Earnings, Guidance Updat... | It also beat out Wall Street's earnings per share estimate of $1.79 for the quarter and was good news for ABBV stock. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVi... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) stock was up today following the release of its earnings report for the first quarter of the year. It also beat out Wall Street's earnings per share estimate of $1.79 for the quarter and was good news for ABBV stock. Source: Black S... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) stock was up today following the release of its earnings report for the first quarter of the year. AbbVie Inc also reported revenue of $7.93 billion for the first quarter of the year. It was also a boon to ABBV stock by coming in ab... |
25,537 | 2018-04-26 00:00:00 UTC | DaVIta (DVA) to Report Q1 Earnings: Is a Beat in Store? | ABBV | https://www.nasdaq.com/articles/davita-dva-to-report-q1-earnings%3A-is-a-beat-in-store-2018-04-26 | null | null | DaVita Inc. 's DVA first-quarter 2018 results are scheduled to release on May 3, after the market closes . DaVita's Dialysis and related lab services business segment has been a consistent driver of revenues for the company. Surging acquisition of dialysis centers also adds to the positives.
Notably, in the fourth quar... | AbbVie Inc. ABBV has an Earnings ESP of +0.06% and a Zacks Rank #3. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report DaVita Inc. (DVA): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report To read this... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report DaVita Inc. (DVA): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV has an Earnings E... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report DaVita Inc. (DVA): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV has an Earnings E... | AbbVie Inc. ABBV has an Earnings ESP of +0.06% and a Zacks Rank #3. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report DaVita Inc. (DVA): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report To read this... |
25,538 | 2018-04-26 00:00:00 UTC | Notable Thursday Option Activity: MAR, GILD, ABBV | ABBV | https://www.nasdaq.com/articles/notable-thursday-option-activity-mar-gild-abbv-2018-04-26 | null | null | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Marriott International, Inc. (Symbol: MAR), where a total volume of 16,829 contracts has been traded thus far today, a contract volume which is representative of approximately 1.7 million underlying sha... | Particularly high volume was seen for the $97.50 strike put option expiring May 04, 2018 , with 2,447 contracts trading so far today, representing approximately 244,700 underlying shares of ABBV. Below is a chart showing GILD's trailing twelve month trading history, with the $85 strike highlighted in orange: And AbbVie... | Below is a chart showing GILD's trailing twelve month trading history, with the $85 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 46,625 contracts, representing approximately 4.7 million underlying shares or approximately 70.7% of ABBV's average daily trading volume over the ... | Below is a chart showing GILD's trailing twelve month trading history, with the $85 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 46,625 contracts, representing approximately 4.7 million underlying shares or approximately 70.7% of ABBV's average daily trading volume over the ... | Below is a chart showing GILD's trailing twelve month trading history, with the $85 strike highlighted in orange: And AbbVie Inc (Symbol: ABBV) saw options trading volume of 46,625 contracts, representing approximately 4.7 million underlying shares or approximately 70.7% of ABBV's average daily trading volume over the ... |
25,539 | 2018-04-26 00:00:00 UTC | Health Care Sector Update for 04/26/2018: ABBV,AXSM | ABBV | https://www.nasdaq.com/articles/health-care-sector-update-04262018-abbvaxsm-2018-04-26 | null | null | Top Health Care Stocks
JNJ +1.48%
PFE +0.74%
ABT +0.43%
MRK -0.27%
AMGN -0.47%
Health care stocks were mostly higher, including a nearly 0.8% gain for the NYSE Health Care Index in recent trade. Also, shares of health care companies in the S&P 500 were up more than 0.8% as a group while the Nasdaq Biotechnology index w... | Among health care stocks moving on news: + AbbVie ( ABBV ) was almost 5% higher Thursday afternoon, staying within relative close distance of its session high, after the company posted Q1 adjusted net income and revenue topping Wall Street expectations. In other sector news: + Axsome Therapeutics ( AXSM ) raced more th... | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Among health care stocks moving on news: + AbbVie ( ABBV ) was almost 5% higher Thursday afternoon, staying within relative close distance of its session high, after the company posted Q... | Among health care stocks moving on news: + AbbVie ( ABBV ) was almost 5% higher Thursday afternoon, staying within relative close distance of its session high, after the company posted Q1 adjusted net income and revenue topping Wall Street expectations. Health care stocks were mostly higher, including a nearly 0.8% gai... | Among health care stocks moving on news: + AbbVie ( ABBV ) was almost 5% higher Thursday afternoon, staying within relative close distance of its session high, after the company posted Q1 adjusted net income and revenue topping Wall Street expectations. Also, shares of health care companies in the S&P 500 were up more ... |
25,540 | 2018-04-26 00:00:00 UTC | AbbVie Breaks Above 200-Day Moving Average - Bullish for ABBV | ABBV | https://www.nasdaq.com/articles/abbvie-breaks-above-200-day-moving-average-bullish-abbv-2018-04-26 | null | null | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $93.67, changing hands as high as $96.55 per share. AbbVie Inc shares are currently trading up about 3.8% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $93.67, changing hands as high as $96.55 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week rang... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $93.67, changing hands as high as $96.55 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week rang... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $93.67, changing hands as high as $96.55 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week rang... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $93.67, changing hands as high as $96.55 per share. AbbVie Inc shares are currently trading up about 3.8% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average... |
25,541 | 2018-04-25 00:00:00 UTC | What's in the Cards for Inogen (INGN) This Earnings Season? | ABBV | https://www.nasdaq.com/articles/whats-in-the-cards-for-inogen-ingn-this-earnings-season-2018-04-25 | null | null | Inogen Inc.'s INGN first-quarter 2018 results are scheduled for release on Apr 30, after the market closes . A broadening Long-term Oxygen Therapy ("LTOT") market, inherent benefits of Portable Oxygen Concentrators ("POC") over traditional delivery model, direct-to-customer business model, underpenetrated international... | AbbVie Inc. ABBV has an Earnings ESP of +0.06% and a Zacks Rank #3. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report To read thi... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV has an Earnings ... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV has an Earnings ... | AbbVie Inc. ABBV has an Earnings ESP of +0.06% and a Zacks Rank #3. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report Inogen, Inc (INGN): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report To read thi... |
25,542 | 2018-04-25 00:00:00 UTC | Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX | ABBV | https://www.nasdaq.com/articles/drug-stock-q1-earnings-due-on-apr-26%3A-abbv-alxn-bmy-vrtx-2018-04-25 | null | null | The Q1 earnings season has started to gather steam. Per the latest Earnings Preview , 87 S&P 500 members - accounting for 17.4% of the index - have already released financial figures as of Apr 20, 2018.
Total earnings for the 87 S&P 500 members that have reported results already are up 25% from the same period last yea... | AbbVie expects Humira sales to reflect a rise in the low-teens band in the imminent earnings release while internationally, the growth rate is projected in a mid-single-digit range, operationally. AbbVie Inc. ABBV is slated to releaseresults before the market opens. Our proven model shows that AbbVie is likely to beat ... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceut... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Vertex Pharmaceut... | AbbVie Inc. ABBV is slated to releaseresults before the market opens. Our proven model shows that AbbVie is likely to beat on earnings in the to-be-reported quarter because it has the right combination of two key ingredients - a positive Earnings ESP of 0.06% and a Zacks Rank # 3 (Hold). AbbVie expects Humira sales to ... |
25,543 | 2018-04-24 00:00:00 UTC | Is a Beat in the Cards for AbbVie (ABBV) in Q1 Earnings? | ABBV | https://www.nasdaq.com/articles/is-a-beat-in-the-cards-for-abbvie-abbv-in-q1-earnings-2018-04-24 | null | null | We expect AbbVie Inc.ABBV to beat expectations when it reports first-quarter 2018 results on Apr 26, before the market opens. Last quarter, the company delivered a positive earnings surprise of 2.78%.
Shares of AbbVie have marginally outperformed the industry so far this year. While the stock has declined 4.1%, the ind... | AbbVie expects Humira sales to reflect a rise in the low-teens band in the imminent earnings release while internationally, the growth rate is projected in a mid-single-digit range, operationally. Moreover, in March 2018, AbbVie's rovalpituzumab tesirine or Rova-T fell short of expectations in a phase II TRINITY study,... | AbbVie Inc. Price and EPS Surprise AbbVie Inc. Price and EPS Surprise | AbbVie Inc. Quote Will You Make a Fortune on the Shift to Electric Cars? Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analy... | Zacks Rank: AbbViehas a Zacks Rank #3, which increases the predictive power of ESP and together with a positive ESP, chances of the stock beating estimates in its upcoming release are always pegged higher. Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Fr... | We expect AbbVie Inc.ABBV to beat expectations when it reports first-quarter 2018 results on Apr 26, before the market opens. Shares of AbbVie have marginally outperformed the industry so far this year. Notably, AbbVie's earnings history is quite impressive with the pharmaceuticals company having outpaced estimates in ... |
25,544 | 2018-04-24 00:00:00 UTC | Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down | ABBV | https://www.nasdaq.com/articles/biogen-biib-q1-earnings-beat-sales-miss-shares-down-2018-04-24 | null | null | Biogen Inc. 's BIIB reported first-quarter 2018 earnings per share of $6.05, which beat the Zacks Consensus Estimate of $5.93 by 2%. Moreover, the bottom line rose 16% year over year.
Sales came in at $3.13 billion, up 11% from the year-ago period. However, the metric marginally missed the Zacks Consensus Estimate of $... | Zinbryta, launched in collaboration with AbbVie ABBV , contributed $1 million to revenues in the first quarter compared with $12 million in fourth-quarter 2017. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Anal... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Zinbryta, launched in collaboration with AbbVie ABBV , c... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Zinbryta, launched in collaboration with AbbVie ABBV , c... | Zinbryta, launched in collaboration with AbbVie ABBV , contributed $1 million to revenues in the first quarter compared with $12 million in fourth-quarter 2017. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Sanofi (SNY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Anal... |
25,545 | 2018-04-24 00:00:00 UTC | What's in Store for AmerisourceBergen (ABC) in Q2 Earnings? | ABBV | https://www.nasdaq.com/articles/whats-in-store-for-amerisourcebergen-abc-in-q2-earnings-2018-04-24 | null | null | AmerisourceBergen Corporation 's ABC second-quarter fiscal 2018 results, scheduled for release on May 2, are expected to show steady growth in the Pharmaceutical Distribution segment, a significant contributor to revenues.
In the last reported quarter, the company posted adjusted earnings of $1.55 per share, beating th... | AbbVie Inc. ABBV has an Earnings ESP of +0.06% and a Zacks Rank #3. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report AmerisourceBergen Corporation (ABC): Free Stock Analysis R... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report AmerisourceBergen Corporation (ABC): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report AmerisourceBergen Corporation (ABC): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV... | AbbVie Inc. ABBV has an Earnings ESP of +0.06% and a Zacks Rank #3. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report AmerisourceBergen Corporation (ABC): Free Stock Analysis R... |
25,546 | 2018-04-24 00:00:00 UTC | Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma | ABBV | https://www.nasdaq.com/articles/get-paid-while-you-wait-3-top-dividend-stocks-big-pharma-2018-04-24 | null | null | AbbVie Inc. (NYSE: ABBV) , Pfizer Inc. (NYSE: PFE) , and Merck & Co. (NYSE: MRK) are developing drugs that could drive profits, and their share prices, through the roof in the years ahead. Of course, there are plenty of reasons things might not work out as planned.
Innovative new drugs make these some of the best big p... | AbbVie Inc. (NYSE: ABBV) , Pfizer Inc. (NYSE: PFE) , and Merck & Co. (NYSE: MRK) are developing drugs that could drive profits, and their share prices, through the roof in the years ahead. While AbbVie and Merck reported one-time charges, Pfizer reported a $9 billion benefit that makes its dividend look a lot more well... | While AbbVie and Merck reported one-time charges, Pfizer reported a $9 billion benefit that makes its dividend look a lot more well-funded than it really is. AbbVie Inc. (NYSE: ABBV) , Pfizer Inc. (NYSE: PFE) , and Merck & Co. (NYSE: MRK) are developing drugs that could drive profits, and their share prices, through th... | AbbVie Inc. (NYSE: ABBV) , Pfizer Inc. (NYSE: PFE) , and Merck & Co. (NYSE: MRK) are developing drugs that could drive profits, and their share prices, through the roof in the years ahead. While AbbVie and Merck reported one-time charges, Pfizer reported a $9 billion benefit that makes its dividend look a lot more well... | Now AbbVie thinks sales of the drug will rise from $18 billion in 2017 to a stunning $21 billion by 2020. AbbVie Inc. (NYSE: ABBV) , Pfizer Inc. (NYSE: PFE) , and Merck & Co. (NYSE: MRK) are developing drugs that could drive profits, and their share prices, through the roof in the years ahead. While AbbVie and Merck re... |
25,547 | 2018-04-24 00:00:00 UTC | Can PBM Unit Boost Express Scripts' (ESRX) Q1 Earnings? | ABBV | https://www.nasdaq.com/articles/can-pbm-unit-boost-express-scripts-esrx-q1-earnings-2018-04-24 | null | null | Express Scripts Holding Company ESRX is scheduled to report first-quarter 2018 results on May 2, after market close. Solid performance by the Pharmacy Benefit Management segment ("PBM") is likely to drive the company's top line. However, the company is getting acquired by Cigna Corporation by the end of 2018.
In the la... | AbbVie Inc. ABBV has an Earnings ESP of +0.06% and a Zacks Rank #3. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report Express Scripts Holding Company (ESRX): Free Stock Analysi... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report Express Scripts Holding Company (ESRX): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. A... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report Express Scripts Holding Company (ESRX): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. A... | AbbVie Inc. ABBV has an Earnings ESP of +0.06% and a Zacks Rank #3. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report Express Scripts Holding Company (ESRX): Free Stock Analysi... |
25,548 | 2018-04-23 00:00:00 UTC | 5 Dividend Growth Stocks With Upside To Analyst Targets | ABBV | https://www.nasdaq.com/articles/5-dividend-growth-stocks-upside-analyst-targets-2018-04-23 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention - and furthermore, "tracking" funds that follow ... | With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Anothe... | The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total ret... | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average ... | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent s... |
25,549 | 2018-04-23 00:00:00 UTC | Q1 Earnings Surprise Well in Cards: Healthcare ETFs to Buy | ABBV | https://www.nasdaq.com/articles/q1-earnings-surprise-well-cards-healthcare-etfs-buy-2018-04-23 | null | null | Healthcare space has been on a tough journey this year. The popular ETF like Health Care Select Sector SPDR Fund XLV has shed 0.4% so farwhile Vanguard Health Care ETF VHT and Fidelity MSCI Health Care Index ETF FHLC have gained at least 0.8%. Meanwhile, iShares U.S. Healthcare ETF IYH has added 0.1%.
The mixed trend i... | The mixed trend is likely to continue heading into the Q1 earnings season as some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb BMY are lined up to report this week and in the next. AbbVie has a Zacks Rank #3 and an Earnings ESP of +0.06%. Click to get ... | The mixed trend is likely to continue heading into the Q1 earnings season as some big names like Pfizer PFE , Merck MRK , Amgen AMGN , AbbVie ABBV , Gilead Sciences GILD and Bristol-Myers Squibb BMY are lined up to report this week and in the next. Click to get this free report Bristol-Myers Squibb Company (BMY): Free ... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report SPDR-HLTH CR (XLV): ETF Research Reports VIPERS-HLTH CR (VHT): ETF Research Report... | Click to get this free report Bristol-Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report SPDR-HLTH CR (XLV): ETF Research Reports VIPERS-HLTH CR (VHT): ETF Research Report... |
25,550 | 2018-04-23 00:00:00 UTC | Will Global Industrial Unit Boost Ecolab's (ECL) Q1 Earnings? | ABBV | https://www.nasdaq.com/articles/will-global-industrial-unit-boost-ecolabs-ecl-q1-earnings-2018-04-23 | null | null | Ecolab Inc. ECL is scheduled to report first-quarter 2018 results on May 1, before the market opens. Solid performance in the Global Industrial segment is likely to drive the top line. Further, an expected improvement in revenues in other segments is likely to help the company generate solid results this season.
Last q... | AbbVie Inc. ABBV has an Earnings ESP of +0.06% and a Zacks Rank #3. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Ecolab Inc. (ECL): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report To read this... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Ecolab Inc. (ECL): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV has an Earnings E... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Ecolab Inc. (ECL): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV has an Earnings E... | AbbVie Inc. ABBV has an Earnings ESP of +0.06% and a Zacks Rank #3. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Ecolab Inc. (ECL): Free Stock Analysis Report Teleflex Incorporated (TFX): Free Stock Analysis Report The Cooper Companies, Inc. (COO): Free Stock Analysis Report To read this... |
25,551 | 2018-04-23 00:00:00 UTC | Is a Beat in Store for Alexion (ALXN) This Earnings Season? | ABBV | https://www.nasdaq.com/articles/is-a-beat-in-store-for-alexion-alxn-this-earnings-season-2018-04-23 | null | null | Alexion Pharmaceuticals, Inc.ALXN is scheduled to report first-quarter 2018 results on Apr 26, before the opening bell.
In the last quarter, the company's earnings surpassed the Zacks Consensus Estimate. Also, Alexion's track record is excellent as it has consistently topped estimates in the last four quarters, with an... | AbbVie Inc. ABBV is scheduled to release results on Apr 26. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this ar... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV is scheduled... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie Inc. ABBV is scheduled... | AbbVie Inc. ABBV is scheduled to release results on Apr 26. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Alexion Pharmaceuticals, Inc. (ALXN): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report To read this ar... |
25,552 | 2018-04-23 00:00:00 UTC | Implied DIVB Analyst Target Price: $29 | ABBV | https://www.nasdaq.com/articles/implied-divb-analyst-target-price-29-2018-04-23 | null | null | Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel , we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares U.S. Dividend and Buyb... | Below is a twelve month price history chart comparing the stock performance of MNK, CELG, and ABBV: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of DIVB's un... | Three of DIVB's underlying holdings with notable upside to their analyst target prices are Mallinckrodt plc (Symbol: MNK), Celgene Corp (Symbol: CELG), and AbbVie Inc (Symbol: ABBV). Similarly, CELG has 36.62% upside from the recent share price of $88.95 if the average analyst target price of $121.52/share is reached, ... | Similarly, CELG has 36.62% upside from the recent share price of $88.95 if the average analyst target price of $121.52/share is reached, and analysts on average are expecting ABBV to reach a target price of $121.08/share, which is 30.75% above the recent price of $92.60. Below is a twelve month price history chart comp... | Below is a twelve month price history chart comparing the stock performance of MNK, CELG, and ABBV: Below is a summary table of the current analyst target prices discussed above: Are analysts justified in these targets, or overly optimistic about where these stocks will be trading 12 months from now? Three of DIVB's un... |
25,553 | 2018-04-23 00:00:00 UTC | What Lies Ahead for Vice ETFs? | ABBV | https://www.nasdaq.com/articles/what-lies-ahead-for-vice-etfs-2018-04-23 | null | null | Vice ETFs primarily target companies dealing in products seen as vices, such as alcohol, tobacco or marijuana. These ETFs are attractive options for those seeking some diversification in their portfolio by investing in the so-called sin stocks.
The need to form such a category was primarily because of some investors' i... | The fund's top three holdings are AbbVie Inc ABBV , Constellation Brands Inc A STZ and MGP Ingredients Inc MGPI , with 1.1%, 0.9% and 0.8% allocation, respectively. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Constellation Brands Inc (STZ): Free Stock Analysis Report ETFMG-WSKY&SPRT (WS... | The fund's top three holdings are AbbVie Inc ABBV , Constellation Brands Inc A STZ and MGP Ingredients Inc MGPI , with 1.1%, 0.9% and 0.8% allocation, respectively. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Constellation Brands Inc (STZ): Free Stock Analysis Report ETFMG-WSKY&SPRT (WS... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Constellation Brands Inc (STZ): Free Stock Analysis Report ETFMG-WSKY&SPRT (WSKY): ETF Research Reports MGP Ingredients, Inc. (MGPI): Free Stock Analysis Report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report ADVSR-VICE ETF (ACT): ET... | Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Constellation Brands Inc (STZ): Free Stock Analysis Report ETFMG-WSKY&SPRT (WSKY): ETF Research Reports MGP Ingredients, Inc. (MGPI): Free Stock Analysis Report GW Pharmaceuticals PLC (GWPH): Free Stock Analysis Report ADVSR-VICE ETF (ACT): ET... |
25,554 | 2018-04-20 00:00:00 UTC | J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit? | ABBV | https://www.nasdaq.com/articles/jj-novartis-q1-earnings-impress%3A-will-others-follow-suit-2018-04-20 | null | null | Johnson & JohnsonJNJ kicked off pharma earnings season on a strong note beating the Zacks Consensus Estimate for both earnings and sales in the first-quarter 2018. J&J's performance was driven by continued positive momentum since the second half of 2017 and improvement in Consumer segment sales.
How Did J&J Perform in ... | The drug is marketed by J&J in partnership with AbbVie, Inc. ABBV . Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free S... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. T... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. T... | The drug is marketed by J&J in partnership with AbbVie, Inc. ABBV . Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free S... |
25,555 | 2018-04-19 00:00:00 UTC | Mylan NV Could Be Closer to a Breakout Than Most Traders Realize | ABBV | https://www.nasdaq.com/articles/mylan-nv-could-be-closer-breakout-most-traders-realize-2018-04-19 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
If it seems like Mylan NV (NASDAQ: MYL ) has gotten far more media attention of late than it usually does - almost all of it bullish - you're not crazy. It has. The recent investor-day event helped the company toot its own horn to be sure, still, MYL stock ... | Humira, is a gastrointestinal drug that maker AbbVie Inc (NYSE: ABBV ) believes it can sell more than $20 billion worth by 2020 . 3 Must-Own Stocks to Buy for Any Portfolio But, it's not just biosimilars that could add major incremental revenue to the mix, nor is it the four other in-house drugs nearing their launch da... | Humira, is a gastrointestinal drug that maker AbbVie Inc (NYSE: ABBV ) believes it can sell more than $20 billion worth by 2020 . InvestorPlace - Stock Market News, Stock Advice & Trading Tips If it seems like Mylan NV (NASDAQ: MYL ) has gotten far more media attention of late than it usually does - almost all of it bu... | Humira, is a gastrointestinal drug that maker AbbVie Inc (NYSE: ABBV ) believes it can sell more than $20 billion worth by 2020 . InvestorPlace - Stock Market News, Stock Advice & Trading Tips If it seems like Mylan NV (NASDAQ: MYL ) has gotten far more media attention of late than it usually does - almost all of it bu... | Humira, is a gastrointestinal drug that maker AbbVie Inc (NYSE: ABBV ) believes it can sell more than $20 billion worth by 2020 . InvestorPlace - Stock Market News, Stock Advice & Trading Tips If it seems like Mylan NV (NASDAQ: MYL ) has gotten far more media attention of late than it usually does - almost all of it bu... |
25,556 | 2018-04-18 00:00:00 UTC | Roche Hemophilia Drug Gets Breakthrough Therapy Designation | ABBV | https://www.nasdaq.com/articles/roche-hemophilia-drug-gets-breakthrough-therapy-designation-2018-04-18 | null | null | Roche Holding AG's RHHBY member Genentech announced that the FDA has granted Breakthrough Therapy Designation to its hemophilia drug, Hemlibra (emicizumab-kxwh). The designation was granted to Hemlibra for treatment of people with hemophilia A without factor VIII inhibitors.
The designation aims to expedite the develop... | A potential approval will further boost Roche's hematology portfolio which includes approved drugs like MabThera/Rituxan, Gazyva/Gazyvaro, Tecentriq and Venclexta We note that Roche is developing Venclexta in collaboration with AbbVie ABBV . AbbVie is commercializing the drug outside the United States. Click to get thi... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. A potential approval will further boost Roche's hema... | Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. A potential approval will further boost Roche's hema... | A potential approval will further boost Roche's hematology portfolio which includes approved drugs like MabThera/Rituxan, Gazyva/Gazyvaro, Tecentriq and Venclexta We note that Roche is developing Venclexta in collaboration with AbbVie ABBV . AbbVie is commercializing the drug outside the United States. Click to get thi... |
25,557 | 2018-04-17 00:00:00 UTC | AbbVie Inc. Is a Clear Value Play in Biotech Stocks | ABBV | https://www.nasdaq.com/articles/abbvie-inc-clear-value-play-biotech-stocks-2018-04-17 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
Since topping over $120 a share three distinct times since February, shares of AbbVie Inc. (NYSE: ABBV ) are still down around 25 percent. Whether the stock was perfectly priced or investors wanted an excuse to lock in profits, ABBV stock still has tremendo... | Only Pfizer Inc. (NYSE: PFE) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) are ahead of AbbVie in developing non-steroidal drugs that treat this skin disease. Takeaway on ABBV stock The market potential for drugs treating lung cancer is big, so the set-back in AbbVie cannot be dismissed. InvestorPlace - Stock Mar... | On March 22, AbbVie reported disappointing Phase 2 data for its Rova-T study that sent its shares lower. Future Upside for ABBV Stock Pivotol trial results for AbbVie's upadacitinib, which treats rheumatoid arthritis; risankizumab, for treating psoriasis, a skin disease; and Murano, which treats patients with relapsed/... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Since topping over $120 a share three distinct times since February, shares of AbbVie Inc. (NYSE: ABBV ) are still down around 25 percent. Future Upside for ABBV Stock Pivotol trial results for AbbVie's upadacitinib, which treats rheumatoid arthritis; risan... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips Since topping over $120 a share three distinct times since February, shares of AbbVie Inc. (NYSE: ABBV ) are still down around 25 percent. For value investors, AbbVie's stock trades at a discount to its peers, so the stock already more than discounts tempor... |
25,558 | 2018-04-17 00:00:00 UTC | 5 Drug Stocks Poised to Surpass on Earnings This Quarter | ABBV | https://www.nasdaq.com/articles/5-drug-stocks-poised-to-surpass-on-earnings-this-quarter-2018-04-17-0 | null | null | The first-quarter earnings season has just kicked off. Per the latest Earnings Preview , the bottom line of S&P 500 companies is expected to increase at a highly impressive rate of 16.6% on a year-over-year basis. This prospective upside marks the maximum quarterly earnings growth pace in seven years. The report furthe... | The three large cap stocks are as follows: Our first pick is AbbVie Inc. ( ABBV ). AbbVie is scheduled to report earnings numbers on Apr 26. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report ... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Aratana Therapeutics, Inc. (PETX): Free Stock Analysis Report Catalent, Inc. (CTLT): Free Stock Analysis Report To read this article on Zacks... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Aratana Therapeutics, Inc. (PETX): Free Stock Analysis Report Catalent, Inc. (CTLT): Free Stock Analysis Report To read this article on Zacks... | The three large cap stocks are as follows: Our first pick is AbbVie Inc. ( ABBV ). AbbVie is scheduled to report earnings numbers on Apr 26. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report ... |
25,559 | 2018-04-17 00:00:00 UTC | J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance | ABBV | https://www.nasdaq.com/articles/jj-jnj-tops-q1-earnings-estimates-raises-sales-guidance-2018-04-17 | null | null | Johnson & JohnsonJNJ kicked off 2018 pharma earnings on a strong note, beating the Zacks Consensus Estimate on both counts in the first quarter of 2018. The drug and consumer products giant upped its previously issued sales outlook for 2018. Shares were up around 1% in pre-market trading .
This year so far, J&J's share... | Please note that J&J markets Imbruvica in partnership with AbbVie, Inc. ABBV . Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this a... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Please note that J&J markets Imbruvica in partn... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Please note that J&J markets Imbruvica in partn... | Please note that J&J markets Imbruvica in partnership with AbbVie, Inc. ABBV . Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this a... |
25,560 | 2018-04-17 00:00:00 UTC | Shire Sells Oncology Unit Ahead of Takeda's Potential Offer | ABBV | https://www.nasdaq.com/articles/shire-sells-oncology-unit-ahead-of-takedas-potential-offer-2018-04-17 | null | null | Shire plcSHPG announced that it has entered into a definitive agreement with French company, Servier to sell its Oncology business. The deal is valued at $2.4 billion and includes global rights to leukemia drug, Oncaspar, and ex-U.S. rights to pancreatic cancer drug, Onivyde. Servier will also add another leukemia drug... | The investor community also believes that a formal takeover offer from Takeda may also trigger bids from other companies, which previously showed interest in Shire including AbbVie ABBV and Pfizer PFE . Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis R... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Shire plc (SHPG): Free Stock Analysis Report To read this article on Zacks.com click here. The investor community also believes that a formal takeover offer from Takeda may also trigger bids from o... | The investor community also believes that a formal takeover offer from Takeda may also trigger bids from other companies, which previously showed interest in Shire including AbbVie ABBV and Pfizer PFE . Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis R... | The investor community also believes that a formal takeover offer from Takeda may also trigger bids from other companies, which previously showed interest in Shire including AbbVie ABBV and Pfizer PFE . Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis R... |
25,561 | 2018-04-17 00:00:00 UTC | 5 Drug Stocks Poised to Surpass on Earnings This Quarter | ABBV | https://www.nasdaq.com/articles/5-drug-stocks-poised-to-surpass-on-earnings-this-quarter-2018-04-17 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The first-quarter earnings season has just kicked off. Per the latest Earnings Preview , the bottom line of S&P 500 companies is expected to increase at a highly impressive rate of 16.6% on a year-over-year basis. This prospective upside marks the maximum q... | Drug Stocks Poised to Surpass on Earnings This Quarter: AbbVie Inc (ABBV) Our first pick is AbbVie Inc (NYSE: ABBV ). 3 Stocks to Gain From the Artificial Intelligence Wave AbbVie is scheduled to report earnings numbers on Apr 26. Per the latest Earnings Preview , the bottom line of S&P 500 companies is expected to inc... | Drug Stocks Poised to Surpass on Earnings This Quarter: AbbVie Inc (ABBV) Our first pick is AbbVie Inc (NYSE: ABBV ). 3 Stocks to Gain From the Artificial Intelligence Wave AbbVie is scheduled to report earnings numbers on Apr 26. Per the Earnings Preview, the broader Medical sector (inclusive of drug, biotech as well ... | Drug Stocks Poised to Surpass on Earnings This Quarter: AbbVie Inc (ABBV) Our first pick is AbbVie Inc (NYSE: ABBV ). 3 Stocks to Gain From the Artificial Intelligence Wave AbbVie is scheduled to report earnings numbers on Apr 26. Per the Earnings Preview, the broader Medical sector (inclusive of drug, biotech as well ... | Drug Stocks Poised to Surpass on Earnings This Quarter: AbbVie Inc (ABBV) Our first pick is AbbVie Inc (NYSE: ABBV ). 3 Stocks to Gain From the Artificial Intelligence Wave AbbVie is scheduled to report earnings numbers on Apr 26. Per the Earnings Preview, the broader Medical sector (inclusive of drug, biotech as well ... |
25,562 | 2018-04-16 00:00:00 UTC | Vanguard S&P 500 ETF Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/vanguard-sp-500-etf-experiences-big-outflow-2018-04-16 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the Vanguard S&P 500 ETF (Symbol: VOO) where we have detected an approximate $137.9 million dollar outflow -- that's a 0.2% decrease week over week (from 357,895,565 to 357,329,244). Among the ... | Among the largest underlying components of VOO, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.1%, Philip Morris International Inc (Symbol: PM) is trading flat, and Bristol-Myers Squibb Co. (Symbol: BMY) is lower by about 7.7%. For a complete list of holdings, visit the VOO Holdings page » The chart below sho... | Among the largest underlying components of VOO, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.1%, Philip Morris International Inc (Symbol: PM) is trading flat, and Bristol-Myers Squibb Co. (Symbol: BMY) is lower by about 7.7%. For a complete list of holdings, visit the VOO Holdings page » The chart below sho... | Among the largest underlying components of VOO, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.1%, Philip Morris International Inc (Symbol: PM) is trading flat, and Bristol-Myers Squibb Co. (Symbol: BMY) is lower by about 7.7%. Looking today at week-over-week shares outstanding changes among the universe of E... | Among the largest underlying components of VOO, in trading today AbbVie Inc (Symbol: ABBV) is up about 1.1%, Philip Morris International Inc (Symbol: PM) is trading flat, and Bristol-Myers Squibb Co. (Symbol: BMY) is lower by about 7.7%. Looking today at week-over-week shares outstanding changes among the universe of E... |
25,563 | 2018-04-15 00:00:00 UTC | Validea's Top Five Healthcare Stocks Based On John Neff - 4/15/2018 | ABBV | https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-john-neff-4152018-2018-04-15 | null | null | The following are the top rated Healthcare stocks according to Validea's Low PE Investor model based on the published strategy of John Neff . This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.
ABBVIE INC ( ABBV ) is a large-cap gr... | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. As of December 31, 2016, the National Group included 84 hospitals, which were located in Alaska, California, Florida, southern Georgia, Idaho, I... | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. For a full detailed analysis using NASDAQ's Guru Analysis tool, click here UNIVERSAL HEALTH SERVICES, INC. ( UHS ) is a large-cap growth stock i... | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Met... | ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Met... |
25,564 | 2018-04-13 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Eli Lilly | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-eli-lilly-2018-04-13 | null | null | One comparison tells a lot about the current situations for AbbVie Inc. (NYSE: ABBV) and Eli Lilly (NYSE: LLY) . AbbVie stock has fallen more than 20% over the last month -- and it's still outperforming Lilly over the past 12 months and so far in 2018.
But that comparison doesn't tell us much about the future prospects... | Beginning in 2023, though, Humira will face competition from biosimilars in the U.S. That means AbbVie will need to offset the inevitable sales decline for its top-selling drug. AbbVie had an even more serious setback in March with disappointing results for rovalpituzumab tesirine (Rova-T) as a third-line treatment for... | Still, AbbVie's pipeline includes several other promising candidates, including cancer drugs Venclexta and veliparib as well as immunology drugs upadacitinib and risankizumab. AbbVie stock currently trades at 11 times expected earnings. One comparison tells a lot about the current situations for AbbVie Inc. (NYSE: ABBV... | Lilly isn't as dependent on one drug as AbbVie is. However, AbbVie appears to still have better growth prospects than Lilly does. With better growth prospects than Lilly, a more attractive valuation, and a stronger dividend, AbbVie certainly appears to be the better stock to buy, in my view. | However, AbbVie appears to still have better growth prospects than Lilly does. With better growth prospects than Lilly, a more attractive valuation, and a stronger dividend, AbbVie certainly appears to be the better stock to buy, in my view. One comparison tells a lot about the current situations for AbbVie Inc. (NYSE:... |
25,565 | 2018-04-13 00:00:00 UTC | Another Shot At This 4-Time Winner -- If We Act Quickly | ABBV | https://www.nasdaq.com/articles/another-shot-4-time-winner-if-we-act-quickly-2018-04-13 | null | null | Last week, I introduced you to Hetty Green . This week, I want to ruminate a little more on her most important piece of wisdom: "Act with thrift and shrewdness and be persistent." As market volatility picks back up, it's a good time take Hetty's approach to heart.
I believe there is a level of shrewdness in ignoring th... | I was thinking about Hetty's shrewdness this week as I ran across some news about AbbVie (NYSE: ABBV ) , one of the world's largest drug makers -- and one of my all-time favorite trade targets. While a number of companies are working on creating Humira biosimilars (similar to generic drugs) in the United States, and Ab... | While a number of companies are working on creating Humira biosimilars (similar to generic drugs) in the United States, and AbbVie is turning to the courts to prevent their launch. I was thinking about Hetty's shrewdness this week as I ran across some news about AbbVie (NYSE: ABBV ) , one of the world's largest drug ma... | How I'm Trading This Stock -- Without Buying A Single Share If you're interested in catching some of the potential upside, you can always buy shares of ABBV and wait for the market to catch up to this well-positioned company. I was thinking about Hetty's shrewdness this week as I ran across some news about AbbVie (NYSE... | While a number of companies are working on creating Humira biosimilars (similar to generic drugs) in the United States, and AbbVie is turning to the courts to prevent their launch. Now is the time to benefit from the higher volatility by selling a put option in ABBV. I was thinking about Hetty's shrewdness this week as... |
25,566 | 2018-04-12 00:00:00 UTC | J&J (JNJ) to Begin Pharma Q1 Earnings: What's in Store? | ABBV | https://www.nasdaq.com/articles/jj-jnj-to-begin-pharma-q1-earnings%3A-whats-in-store-2018-04-12 | null | null | We expect Johnson & JohnsonJNJ , a healthcare bellwether, to beat expectations when it reports first-quarter 2018 results on April 17, before market opens. Last quarter, the company delivered a positive earnings surprise of 1.16%.
J&J's performance has been pretty impressive, with the company exceeding earnings expecta... | AbbVie, Inc. ABBV has an Earnings ESP of +0.47% and a Zacks Rank #3. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article o... | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc. ABBV has an Earnings ESP of +0.4... | Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie, Inc. ABBV has an Earnings ESP of +0.4... | AbbVie, Inc. ABBV has an Earnings ESP of +0.47% and a Zacks Rank #3. Click to get this free report Johnson & Johnson (JNJ): Free Stock Analysis Report GlaxoSmithKline plc (GSK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report To read this article o... |
25,567 | 2018-04-12 00:00:00 UTC | Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar | ABBV | https://www.nasdaq.com/articles/mylan-fujifilm-kyowa-team-up-to-market-humira-biosimilar-2018-04-12 | null | null | Mylan N.V.MYL is partnering with Fujifilm Kyowa Kirin Biologics Co., Ltd. to commercialize a biosimilar to AbbVie's ABBV blockbuster arthritis drug Humira (adalimumab). Adalimumab is developed by Fujifilm Kyowa Kirin Biologics.
Mylan intends to seek approval and commercialize the product in Europe. The European Medicin... | Mylan N.V.MYL is partnering with Fujifilm Kyowa Kirin Biologics Co., Ltd. to commercialize a biosimilar to AbbVie's ABBV blockbuster arthritis drug Humira (adalimumab). Another biotechnology company, Amgen AMGN , is also expected to launch its biosimilar version of Humira, in the EU come October this year as Amjevita, ... | Mylan N.V.MYL is partnering with Fujifilm Kyowa Kirin Biologics Co., Ltd. to commercialize a biosimilar to AbbVie's ABBV blockbuster arthritis drug Humira (adalimumab). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Sto... | Mylan N.V.MYL is partnering with Fujifilm Kyowa Kirin Biologics Co., Ltd. to commercialize a biosimilar to AbbVie's ABBV blockbuster arthritis drug Humira (adalimumab). Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report Amgen Inc. (AMGN): Free Stock Analysis Report Biogen Inc. (BIIB): Free Sto... | Mylan N.V.MYL is partnering with Fujifilm Kyowa Kirin Biologics Co., Ltd. to commercialize a biosimilar to AbbVie's ABBV blockbuster arthritis drug Humira (adalimumab). Another biotechnology company, Amgen AMGN , is also expected to launch its biosimilar version of Humira, in the EU come October this year as Amjevita, ... |
25,568 | 2018-04-11 00:00:00 UTC | FDA Prolongs Review Date for AbbVie Endometriosis Candidate | ABBV | https://www.nasdaq.com/articles/fda-prolongs-review-date-for-abbvie-endometriosis-candidate-2018-04-11 | null | null | AbbVie Inc.ABBV and partner Neurocrine Biosciences announced that the FDA has extended the review period of marketing application for the companies' pipeline candidate, elagolix, by three months. As a result, the regulatory body will now announce its decision by the third quarter of 2018 instead of the previously antic... | AbbVie Inc.ABBV and partner Neurocrine Biosciences announced that the FDA has extended the review period of marketing application for the companies' pipeline candidate, elagolix, by three months. However, the regulatory body requested for an extended time frame to review additional information, provided by AbbVie along... | AbbVie Inc.ABBV and partner Neurocrine Biosciences announced that the FDA has extended the review period of marketing application for the companies' pipeline candidate, elagolix, by three months. AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie carries a Zacks Rank #3 (Hold). Click ... | AbbVie Inc. Price AbbVie Inc. Price | AbbVie Inc. Quote Zacks Rank & Key Picks AbbVie carries a Zacks Rank #3 (Hold). Click to get this free report Allergan plc (AGN): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Ligand Pharmaceuticals Incorporated (LGND): Free Stock Analysis Report Infinit... | AbbVie is looking to get elagolix approved as an oral medicine for pain management associated with endometriosis. However, the regulatory body requested for an extended time frame to review additional information, provided by AbbVie along with its NDA pertaining to liver function test results. AbbVie Inc.ABBV and partn... |
25,569 | 2018-04-11 00:00:00 UTC | Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis | ABBV | https://www.nasdaq.com/articles/biotech-stock-roundup%3A-spectrum-up-incyte-down-avexis-to-merge-with-novartis-2018-04-11 | null | null | The biotech sector was on a bumpy ride over the week as shares of Spectrum surged on positive data from a phase II study, while that of Incyte plunged on the failure of melanoma study. In an effort to bolster its presence in the gene therapy space Swiss giant Novartis announced the acquisition of AveXis Inc.
Spectrum S... | (Read more: Conatus' Emricasan Fails in Phase II Study, Shares Sink ) Biogen Settles Litigation With AbbVie For Humira Biosimilar : Biogen Inc. BIIB and partner Samsung Bioepis announced an agreement with AbbVie ABBV for the commercialization of Imraldi, a biosimilar of Humira. Per the terms, AbbVie will grant patent l... | (Read more: Conatus' Emricasan Fails in Phase II Study, Shares Sink ) Biogen Settles Litigation With AbbVie For Humira Biosimilar : Biogen Inc. BIIB and partner Samsung Bioepis announced an agreement with AbbVie ABBV for the commercialization of Imraldi, a biosimilar of Humira. Click to get this free report Novartis AG... | Click to get this free report Novartis AG (NVS): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Conatus Pharmaceuticals Inc. (CNAT): Free Stock Analysis Report Incyte Corporation (INCY): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report AveXis, Inc. (AVXS): Free Stock ... | (Read more: Conatus' Emricasan Fails in Phase II Study, Shares Sink ) Biogen Settles Litigation With AbbVie For Humira Biosimilar : Biogen Inc. BIIB and partner Samsung Bioepis announced an agreement with AbbVie ABBV for the commercialization of Imraldi, a biosimilar of Humira. Per the terms, AbbVie will grant patent l... |
25,570 | 2018-04-10 00:00:00 UTC | Ex-Dividend Reminder: American Eagle Outfitters, Buckle and AbbVie | ABBV | https://www.nasdaq.com/articles/ex-dividend-reminder-american-eagle-outfitters-buckle-and-abbvie-2018-04-10 | null | null | Looking at the universe of stocks we cover at Dividend Channel , on 4/12/18, American Eagle Outfitters, Inc. (Symbol: AEO), Buckle, Inc. (Symbol: BKE), and AbbVie Inc (Symbol: ABBV) will all trade ex-dividend for their respective upcoming dividends. American Eagle Outfitters, Inc. will pay its quarterly dividend of $0.... | If they do continue, the current estimated yields on annualized basis would be 2.58% for American Eagle Outfitters, Inc., 4.42% for Buckle, Inc. , and 4.20% for AbbVie Inc. Looking at the universe of stocks we cover at Dividend Channel , on 4/12/18, American Eagle Outfitters, Inc. (Symbol: AEO), Buckle, Inc. (Symbol: B... | Looking at the universe of stocks we cover at Dividend Channel , on 4/12/18, American Eagle Outfitters, Inc. (Symbol: AEO), Buckle, Inc. (Symbol: BKE), and AbbVie Inc (Symbol: ABBV) will all trade ex-dividend for their respective upcoming dividends. American Eagle Outfitters, Inc. will pay its quarterly dividend of $0.... | Looking at the universe of stocks we cover at Dividend Channel , on 4/12/18, American Eagle Outfitters, Inc. (Symbol: AEO), Buckle, Inc. (Symbol: BKE), and AbbVie Inc (Symbol: ABBV) will all trade ex-dividend for their respective upcoming dividends. American Eagle Outfitters, Inc. will pay its quarterly dividend of $0.... | If they do continue, the current estimated yields on annualized basis would be 2.58% for American Eagle Outfitters, Inc., 4.42% for Buckle, Inc. , and 4.20% for AbbVie Inc. Looking at the universe of stocks we cover at Dividend Channel , on 4/12/18, American Eagle Outfitters, Inc. (Symbol: AEO), Buckle, Inc. (Symbol: B... |
25,571 | 2018-04-08 00:00:00 UTC | Here's Why AbbVie Inc. Fell 18.3% in March | ABBV | https://www.nasdaq.com/articles/heres-why-abbvie-inc-fell-183-march-2018-04-08 | null | null | What happened
Shares of AbbVie Inc. (NYSE: ABBV) , a big U.S. pharma, dropped 18.3% in March, according to data from S&P Global Market Intelligence . A high-profile lung cancer candidate missed the mark during an important trial.
So what
Rova-T was the early clinical-stage asset that inspired AbbVie to pay a stunning $... | What happened Shares of AbbVie Inc. (NYSE: ABBV) , a big U.S. pharma, dropped 18.3% in March, according to data from S&P Global Market Intelligence . To justify the splurge, AbbVie pointed to a 44% response rate among a group of advanced stage small cell lung cancer patients with tumors that express Rova-T's target. Se... | To justify the splurge, AbbVie pointed to a 44% response rate among a group of advanced stage small cell lung cancer patients with tumors that express Rova-T's target. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. What happened Shar... | To justify the splurge, AbbVie pointed to a 44% response rate among a group of advanced stage small cell lung cancer patients with tumors that express Rova-T's target. The market shaved around $23 billion from AbbVie's market cap on the day the company announced it wouldn't be seeking an accelerated approval for Rova-T... | To justify the splurge, AbbVie pointed to a 44% response rate among a group of advanced stage small cell lung cancer patients with tumors that express Rova-T's target. The market shaved around $23 billion from AbbVie's market cap on the day the company announced it wouldn't be seeking an accelerated approval for Rova-T... |
25,572 | 2018-04-06 00:00:00 UTC | 3 High-Yield Stocks at Rock-Bottom Prices | ABBV | https://www.nasdaq.com/articles/3-high-yield-stocks-rock-bottom-prices-2018-04-06 | null | null | Often, dividend yields soar because a company's share price is falling thanks to a business in disrepair. That can make buying high-yield stocks risky, so it pays to be selective and focus only on businesses that have the best odds of getting back on track. With that in mind, we asked some of our top Motley Fool invest... | Read on to find out why it might be a smart time to add L Brands (NYSE: LB) , GameStop Corp. (NYSE: GME) , and AbbVie, Inc. (NYSE: ABBV) to income portfolios now. A beaten-down biopharma with a top-tier dividend yield Todd Campbell (AbbVie): Recently, AbbVie rolled out disappointing data for one of its most prized clin... | A beaten-down biopharma with a top-tier dividend yield Todd Campbell (AbbVie): Recently, AbbVie rolled out disappointing data for one of its most prized clinical-stage drugs, Rova-T. Read on to find out why it might be a smart time to add L Brands (NYSE: LB) , GameStop Corp. (NYSE: GME) , and AbbVie, Inc. (NYSE: ABBV) ... | Read on to find out why it might be a smart time to add L Brands (NYSE: LB) , GameStop Corp. (NYSE: GME) , and AbbVie, Inc. (NYSE: ABBV) to income portfolios now. A beaten-down biopharma with a top-tier dividend yield Todd Campbell (AbbVie): Recently, AbbVie rolled out disappointing data for one of its most prized clin... | The Rova-T news sent AbbVie's shares reeling and, in turn, its dividend yield soaring. Read on to find out why it might be a smart time to add L Brands (NYSE: LB) , GameStop Corp. (NYSE: GME) , and AbbVie, Inc. (NYSE: ABBV) to income portfolios now. A beaten-down biopharma with a top-tier dividend yield Todd Campbell (... |
25,573 | 2018-04-06 00:00:00 UTC | Biogen Cracks the Case With AbbVie for Humira Biosimilar | ABBV | https://www.nasdaq.com/articles/biogen-cracks-the-case-with-abbvie-for-humira-biosimilar-2018-04-06 | null | null | Biogen Inc.BIIB and partner Samsung Bioepis have announced resolution of an ongoing patent dispute with AbbVie ABBV regarding Biogen's biosimilar version (Imraldi) of AbbVie's blockbuster arthritis drug, Humira, in the EU. Per the settlement agreement, Biogen/Samsung Bioepis plans to launch Imraldi in Europe on Oct 16,... | Also in the United States, Samsung Bioepis entered into a settlement agreement with AbbVie, which would allow the former to bring Humira biosimilar into the U.S. market by Jan 31, 2023. Another biotechnology company, Amgen (AMGN), is also expected to launch its biosimilar version of Humira, in the EU come October this ... | Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Biogen Inc. (BIIB): Free Stock Analysis Report To read this article on Zacks.com click here. Biogen Inc.BIIB and partner Samsung Bioepis have ann... | Biogen Inc.BIIB and partner Samsung Bioepis have announced resolution of an ongoing patent dispute with AbbVie ABBV regarding Biogen's biosimilar version (Imraldi) of AbbVie's blockbuster arthritis drug, Humira, in the EU. Click to get this free report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MR... | Biogen Inc.BIIB and partner Samsung Bioepis have announced resolution of an ongoing patent dispute with AbbVie ABBV regarding Biogen's biosimilar version (Imraldi) of AbbVie's blockbuster arthritis drug, Humira, in the EU. Also in the United States, Samsung Bioepis entered into a settlement agreement with AbbVie, which... |
25,574 | 2018-04-06 00:00:00 UTC | iShares S&P 500 Growth ETF Experiences Big Outflow | ABBV | https://www.nasdaq.com/articles/ishares-sp-500-growth-etf-experiences-big-outflow-2018-04-06 | null | null | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel , one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $156.1 million dollar outflow -- that's a 0.8% decrease week over week (from 129,450,000 to 128,450,000). Amon... | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.2%, Broadcom Ltd (Symbol: AVGO) is down about 0.7%, and Celgene Corp (Symbol: CELG) is lower by about 0.1%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price per... | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.2%, Broadcom Ltd (Symbol: AVGO) is down about 0.7%, and Celgene Corp (Symbol: CELG) is lower by about 0.1%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price per... | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.2%, Broadcom Ltd (Symbol: AVGO) is down about 0.7%, and Celgene Corp (Symbol: CELG) is lower by about 0.1%. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channe... | Among the largest underlying components of IVW, in trading today AbbVie Inc (Symbol: ABBV) is up about 0.2%, Broadcom Ltd (Symbol: AVGO) is down about 0.7%, and Celgene Corp (Symbol: CELG) is lower by about 0.1%. For a complete list of holdings, visit the IVW Holdings page » The chart below shows the one year price per... |
25,575 | 2018-04-05 00:00:00 UTC | After Hours Most Active for Apr 5, 2018 : CZR, MSFT, KEY, JPM, CSCO, CMCSA, MU, MXIM, GE, NUE, ABBV, PFE | ABBV | https://www.nasdaq.com/articles/after-hours-most-active-apr-5-2018-czr-msft-key-jpm-csco-cmcsa-mu-mxim-ge-nue-abbv-pfe | null | null | The NASDAQ 100 After Hours Indicator is down -3.41 to 6,591.43. The total After hours volume is currently 72,403,769 shares traded.
The following are the most active stocks for the after hours session :
Caesars Entertainment Corporation ( CZR ) is unchanged at $11.50, with 33,486,748 shares traded. As reported by Zacks... | AbbVie Inc. ( ABBV ) is -0.07 at $92.14, with 1,067,550 shares traded. ABBV's current last sale is 73.71% of the target price of $125. The following are the most active stocks for the after hours session : Caesars Entertainment Corporation ( CZR ) is unchanged at $11.50, with 33,486,748 shares traded. | The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AbbVie Inc. ( ABBV ) is -0.07 at $92.14, with 1,067,550 shares traded. ABBV's current last sale is 73.71% of the target price of $125. | AbbVie Inc. ( ABBV ) is -0.07 at $92.14, with 1,067,550 shares traded. ABBV's current last sale is 73.71% of the target price of $125. As reported by Zacks, the current mean recommendation for MSFT is in the "buy range". | AbbVie Inc. ( ABBV ) is -0.07 at $92.14, with 1,067,550 shares traded. ABBV's current last sale is 73.71% of the target price of $125. The following are the most active stocks for the after hours session : Caesars Entertainment Corporation ( CZR ) is unchanged at $11.50, with 33,486,748 shares traded. |
25,576 | 2018-04-04 00:00:00 UTC | Which Big Pharma CEOs Least Deserved Their Big Pay Increases? | ABBV | https://www.nasdaq.com/articles/which-big-pharma-ceos-least-deserved-their-big-pay-increases-2018-04-04 | null | null | You might be surprised by the pay increases given to big pharma CEOs in 2017.
The average pay increase for all U.S. workers last year was 3.1%, according to the Society for Human Resource Management. But based on recent regulatory filings submitted by several major biopharmaceutical companies, their CEOs received salar... | AbbVie's total return, including stock gains and dividend reinvestment, was by far the greatest of these big pharma companies. The biggest of the big pharma companies reporting their executive compensation for 2017 so far are AbbVie (NYSE: ABBV) , Bristol-Myers Squibb (NYSE: BMY) , Gilead Sciences (NASDAQ: GILD) , John... | The biggest of the big pharma companies reporting their executive compensation for 2017 so far are AbbVie (NYSE: ABBV) , Bristol-Myers Squibb (NYSE: BMY) , Gilead Sciences (NASDAQ: GILD) , Johnson & Johnson (NYSE: JNJ) , and Pfizer (NYSE: PFE) . Pfizer CEO Ian Read received a salary increase of 2.7%, while AbbVie CEO R... | The biggest of the big pharma companies reporting their executive compensation for 2017 so far are AbbVie (NYSE: ABBV) , Bristol-Myers Squibb (NYSE: BMY) , Gilead Sciences (NASDAQ: GILD) , Johnson & Johnson (NYSE: JNJ) , and Pfizer (NYSE: PFE) . Pfizer CEO Ian Read received a salary increase of 2.7%, while AbbVie CEO R... | The biggest of the big pharma companies reporting their executive compensation for 2017 so far are AbbVie (NYSE: ABBV) , Bristol-Myers Squibb (NYSE: BMY) , Gilead Sciences (NASDAQ: GILD) , Johnson & Johnson (NYSE: JNJ) , and Pfizer (NYSE: PFE) . Pfizer CEO Ian Read received a salary increase of 2.7%, while AbbVie CEO R... |
25,577 | 2018-04-03 00:00:00 UTC | Aeglea Initiates Lung Cancer Combination Study With Keytruda | ABBV | https://www.nasdaq.com/articles/aeglea-initiates-lung-cancer-combination-study-with-keytruda-2018-04-03 | null | null | Aeglea BioTherapeutics, Inc.AGLE announced that it has initiated dosing of patients in two studies evaluating its lung cancer candidate, pegzilarginase, in small cell lung cancer ("SCLC").
A cohort expansion phase I study is evaluating pegzilarginase as monotherapy in SCLC patients. The other one is phase I/II study ev... | AbbVie ABBV and Bristol-Myers have collaborated to develop rovalpituzumab tesirine in combination with Opdivo and Yervoy in a phase I study. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report ... | Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Aeglea BioTherapeutics, Inc. (AGLE): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV and Bristol-Myers h... | Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Aeglea BioTherapeutics, Inc. (AGLE): Free Stock Analysis Report To read this article on Zacks.com click here. AbbVie ABBV and Bristol-Myers h... | AbbVie ABBV and Bristol-Myers have collaborated to develop rovalpituzumab tesirine in combination with Opdivo and Yervoy in a phase I study. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report ... |
25,578 | 2018-04-03 00:00:00 UTC | 2 Big Biotech Bargains You Can Buy Now | ABBV | https://www.nasdaq.com/articles/2-big-biotech-bargains-you-can-buy-now-2018-04-03 | null | null | Biotech stocks aren't usually known for being great bargains. In many cases, biotechs command premium valuations. But that's not the case for two big biotechs.
Both AbbVie (NYSE: ABBV) and Celgene (NASDAQ: CELG) have seen their stock prices fall significantly. These big biotechs now claim really low earnings multiples,... | A clinical setback for rovalpituzumab tesirine (Rova-T) as a third-line treatment for relapsed/refractory small cell lung cancer (SCLC) caused AbbVie's decline. Both AbbVie (NYSE: ABBV) and Celgene (NASDAQ: CELG) have seen their stock prices fall significantly. Why they're beaten down AbbVie's share price is down more ... | Prior to the Rova-T setback, AbbVie expected to generate risk-adjusted non-Humira sales of $35 billion by 2025. It only makes sense to wonder if there's a catch with biotech stocks like AbbVie and Celgene that are cheap yet still have great growth prospects. Both AbbVie (NYSE: ABBV) and Celgene (NASDAQ: CELG) have seen... | It only makes sense to wonder if there's a catch with biotech stocks like AbbVie and Celgene that are cheap yet still have great growth prospects. AbbVie and Celgene should both have plenty of time for other drugs to ramp up sales to offset those declines. But I think AbbVie and Celgene are biotech bargains right now t... | Why they're bargains Because of these factors, AbbVie stock now trades at 10.6 times expected earnings. Both AbbVie (NYSE: ABBV) and Celgene (NASDAQ: CELG) have seen their stock prices fall significantly. Why they're beaten down AbbVie's share price is down more than 20% over the last three weeks. |
25,579 | 2018-04-03 00:00:00 UTC | Tuesday Sector Laggards: Utilities, Healthcare | ABBV | https://www.nasdaq.com/articles/tuesday-sector-laggards-utilities-healthcare-2018-04-03 | null | null | In afternoon trading on Tuesday, Utilities stocks are the worst performing sector, up 0.1%. Within that group, Sempra Energy (Symbol: SRE) and American Water Works Co, Inc. (Symbol: AWK) are two large stocks that are lagging, showing a loss of 0.7% and 0.5%, respectively. Among utilities ETFs , one ETF following the se... | Combined, ABBV and CELG make up approximately 6.8% of the underlying holdings of XLV. Among large Healthcare stocks, AbbVie Inc (Symbol: ABBV) and Celgene Corp (Symbol: CELG) are the most notable, showing a loss of 2.3% and 1.2%, respectively. AbbVie Inc, meanwhile, is down 6.89% year-to-date, and Celgene Corp, is down... | Among large Healthcare stocks, AbbVie Inc (Symbol: ABBV) and Celgene Corp (Symbol: CELG) are the most notable, showing a loss of 2.3% and 1.2%, respectively. AbbVie Inc, meanwhile, is down 6.89% year-to-date, and Celgene Corp, is down 17.54% year-to-date. Combined, ABBV and CELG make up approximately 6.8% of the underl... | Among large Healthcare stocks, AbbVie Inc (Symbol: ABBV) and Celgene Corp (Symbol: CELG) are the most notable, showing a loss of 2.3% and 1.2%, respectively. AbbVie Inc, meanwhile, is down 6.89% year-to-date, and Celgene Corp, is down 17.54% year-to-date. Combined, ABBV and CELG make up approximately 6.8% of the underl... | Among large Healthcare stocks, AbbVie Inc (Symbol: ABBV) and Celgene Corp (Symbol: CELG) are the most notable, showing a loss of 2.3% and 1.2%, respectively. AbbVie Inc, meanwhile, is down 6.89% year-to-date, and Celgene Corp, is down 17.54% year-to-date. Combined, ABBV and CELG make up approximately 6.8% of the underl... |
25,580 | 2018-04-02 00:00:00 UTC | AbbVie Breaks Below 200-Day Moving Average - Notable for ABBV | ABBV | https://www.nasdaq.com/articles/abbvie-breaks-below-200-day-moving-average-notable-abbv-2018-04-02 | null | null | In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $91.84, changing hands as low as $90.30 per share. AbbVie Inc shares are currently trading down about 3.4% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average:... | In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $91.84, changing hands as low as $90.30 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week range i... | In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $91.84, changing hands as low as $90.30 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week range i... | In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $91.84, changing hands as low as $90.30 per share. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average: Looking at the chart above, ABBV's low point in its 52 week range i... | In trading on Monday, shares of AbbVie Inc (Symbol: ABBV) crossed below their 200 day moving average of $91.84, changing hands as low as $90.30 per share. AbbVie Inc shares are currently trading down about 3.4% on the day. The chart below shows the one year performance of ABBV shares, versus its 200 day moving average:... |
25,581 | 2018-04-01 00:00:00 UTC | How Safe Is AbbVie, Inc.'s Dividend Now? | ABBV | https://www.nasdaq.com/articles/how-safe-abbvie-incs-dividend-now-2018-04-01 | null | null | AbbVie Inc. 's (NYSE: ABBV) treated shareholders to some hefty dividend bumps since its inception five years ago, but a 35% raise announced in February was the biggest yet. Not long after announcing the payout boost and another $10 billion stock repurchase program, a high-profile clinical trial failure knocked AbbVie's... | So far, sales haven't been worth mentioning, but results from a combination trial designed to expand Venetoclax to a larger population suggest it can still generate several billion annually for AbbVie. AbbVie Inc. 's (NYSE: ABBV) treated shareholders to some hefty dividend bumps since its inception five years ago, but ... | Not long after announcing the payout boost and another $10 billion stock repurchase program, a high-profile clinical trial failure knocked AbbVie's stock down a few pegs. Earlier this year, AbbVie predicted sales of drugs excluding Humira would rise from $9.8 billion in 2017 to $35 billion in 2025. Know what to expect ... | Not long after announcing the payout boost and another $10 billion stock repurchase program, a high-profile clinical trial failure knocked AbbVie's stock down a few pegs. Earlier this year, AbbVie predicted sales of drugs excluding Humira would rise from $9.8 billion in 2017 to $35 billion in 2025. AbbVie's share of Im... | Biosimilars aren't the only competitive threat that could make it hard for AbbVie to keep raising its dividend. 10 stocks we like better than AbbVie When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. AbbVie Inc. 's (NYSE: ABBV) treated shareholders to some hefty dividend bumps since i... |
25,582 | 2018-04-01 00:00:00 UTC | Better Buy: AbbVie Inc. vs. Johnson & Johnson | ABBV | https://www.nasdaq.com/articles/better-buy-abbvie-inc-vs-johnson-johnson-2018-04-01 | null | null | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) battle each other in the marketplace every day. But they also are partners. That's not an unusual scenario in the biopharmaceutical world today.
Since being spun off from parent Abbott Labs (NYSE: ABT) in 2013, AbbVie stock's performance has more than doubled that o... | AbbVie's historical growth stemmed primarily from Humira, the top-selling drug in the world. AbbVie CFO Bill Chase recently stated that the drugmaker's pipeline has "almost an embarrassment of riches." But challenges exist for both: AbbVie announced a significant pipeline setback recently, when Rova-T failed in a phase... | AbbVie shares trade at less than 11 times expected earnings. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) battle each other in the marketplace every day. Since being spun off from parent Abbott Labs (NYSE: ABT) in 2013, AbbVie stock's performance has more than doubled that of Johnson & Johnson. | Since being spun off from parent Abbott Labs (NYSE: ABT) in 2013, AbbVie stock's performance has more than doubled that of Johnson & Johnson. Johnson & Johnson hasn't achieved the rate of earnings growth or stock gains that AbbVie has in recent years. AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) battle each ot... | AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) battle each other in the marketplace every day. Since being spun off from parent Abbott Labs (NYSE: ABT) in 2013, AbbVie stock's performance has more than doubled that of Johnson & Johnson. The case for AbbVie Investors typically fall into one of three categories: g... |
25,583 | 2018-03-30 00:00:00 UTC | 3 Top Healthcare Stocks to Buy Right Now | ABBV | https://www.nasdaq.com/articles/3-top-healthcare-stocks-buy-right-now-2018-03-30 | null | null | People need healthcare no matter what's happening to the rest of the economy or their portfolios. That makes strong companies in that critical industry wonderful businesses to own. We asked three Foolish investors which healthcare stocks looked like they were worth buying right now, and they picked AbbVie (NYSE: ABBV) ... | We asked three Foolish investors which healthcare stocks looked like they were worth buying right now, and they picked AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Hologic (NASDAQ: HOLX) . Something for everyone Keith Speights (AbbVie) : You can't knock AbbVie's performance. Can AbbVie keep the momentum going? | Despite its strong growth prospects and dividend, AbbVie's shares trade at less than 12 times expected earnings. We asked three Foolish investors which healthcare stocks looked like they were worth buying right now, and they picked AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Hologic (NASDAQ: HOLX) . Something for ev... | We asked three Foolish investors which healthcare stocks looked like they were worth buying right now, and they picked AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Hologic (NASDAQ: HOLX) . Something for everyone Keith Speights (AbbVie) : You can't knock AbbVie's performance. Can AbbVie keep the momentum going? | What's not to like about AbbVie? We asked three Foolish investors which healthcare stocks looked like they were worth buying right now, and they picked AbbVie (NYSE: ABBV) , Pfizer (NYSE: PFE) , and Hologic (NASDAQ: HOLX) . Something for everyone Keith Speights (AbbVie) : You can't knock AbbVie's performance. |
25,584 | 2018-03-29 00:00:00 UTC | Geron Corp. Skyrocketed and AbbVie Inc. Crashed -- Are These Stocks Buys? | ABBV | https://www.nasdaq.com/articles/geron-corp-skyrocketed-and-abbvie-inc-crashed-are-these-stocks-buys-2018-03-29 | null | null | Optimism that Johnson & Johnson (NYSE: JNJ) will choose to continue developing its lead drug sent Geron Corp .'s (NASDAQ: GERN) stock soaring recently. However, there are some reasons investors ought to tamp down their enthusiasm. Can Geron Corp.'s imetelstat overcome obstacles and reshape how doctors treat a billion-d... | Also, the two weigh in on bad news that recently caused AbbVie Inc. 's (NYSE: ABBV) shares to tumble. Is AbbVie's stock now a bargain-bin buy? Moving onto the second half of our show today, we wanted to talk a little bit about AbbVie. | Also, the two weigh in on bad news that recently caused AbbVie Inc. 's (NYSE: ABBV) shares to tumble. Is AbbVie's stock now a bargain-bin buy? Moving onto the second half of our show today, we wanted to talk a little bit about AbbVie. | Also, the two weigh in on bad news that recently caused AbbVie Inc. 's (NYSE: ABBV) shares to tumble. Is AbbVie's stock now a bargain-bin buy? Moving onto the second half of our show today, we wanted to talk a little bit about AbbVie. | Also, the two weigh in on bad news that recently caused AbbVie Inc. 's (NYSE: ABBV) shares to tumble. Is AbbVie's stock now a bargain-bin buy? Moving onto the second half of our show today, we wanted to talk a little bit about AbbVie. |
25,585 | 2018-03-28 00:00:00 UTC | AbbVie a Top Ranked SAFE Dividend Stock With 4.2% Yield (ABBV) | ABBV | https://www.nasdaq.com/articles/abbvie-top-ranked-safe-dividend-stock-42-yield-abbv-2018-03-28 | null | null | AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. 25'' list, signifying a stock with above-average ''DividendRank'' statistics including a strong 4.2% yield, as well as a superb track record of at least two decades of dividend growth, according to the most recent ''DividendRank'' report.
Accor... | Below is a long-term dividend history chart for ABBV, which the report stressed as being of key importance. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel , AbbVie Inc is a member of the iShares S&P 1500 Index ETF ( ITOT ), and is also an underlyin... | AbbVie Inc (Symbol: ABBV) made the "Dividend Channel S.A.F.E. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel , AbbVie Inc is a member of the iShares S&P 1500 Index ETF ( ITOT ), and is also an underlying holding representing 1.18% of the SPDR S&P D... | According to the ETF Finder at ETF Channel , AbbVie Inc is a member of the iShares S&P 1500 Index ETF ( ITOT ), and is also an underlying holding representing 1.18% of the SPDR S&P Dividend ETF ( SDY ), which holds $175,601,068 worth of ABBV shares. AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A... | AbbVie Inc (Symbol: ABBV) has been named to the Dividend Channel ''S.A.F.E. According to the ETF Finder at ETF Channel , AbbVie Inc is a member of the iShares S&P 1500 Index ETF ( ITOT ), and is also an underlying holding representing 1.18% of the SPDR S&P Dividend ETF ( SDY ), which holds $175,601,068 worth of ABBV sh... |
25,586 | 2018-03-28 00:00:00 UTC | Validea Peter Lynch Strategy Daily Upgrade Report - 3/28/2018 | ABBV | https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-3282018-2018-03-28 | null | null | The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch . This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.
ROLLS-ROYCE HOLDING PLC (ADR) ( RYCEY ) is a large-cap value stock... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. This strategy looks for stocks trading at a reasonable price relative... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Its segments include Civil Aerospace, which is engaged in the develop... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. Its segments include Civil Aerospace, which is engaged in the develop... | For a full detailed analysis using NASDAQ's Guru Analysis tool, click here ABBVIE INC ( ABBV ) is a large-cap growth stock in the Biotechnology & Drugs industry. Company Description: AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The following are today's upgrades for Validea's P/E/Growth Investor ... |
25,587 | 2018-03-27 00:00:00 UTC | How Risky Is AbbVie's Pipeline? | ABBV | https://www.nasdaq.com/articles/how-risky-abbvies-pipeline-2018-03-27 | null | null | AbbVie (NYSE: ABBV) continues to reel from its announcement last week of very disappointing results for rovalpituzumab tesirine (Rova-T) as a third-line treatment for relapsed/refractory small cell lung cancer (SCLC). Over one-fifth of the big pharma company's market cap has been wiped out following news of the Rova-T ... | AbbVie (NYSE: ABBV) continues to reel from its announcement last week of very disappointing results for rovalpituzumab tesirine (Rova-T) as a third-line treatment for relapsed/refractory small cell lung cancer (SCLC). AbbVie hopes to win additional approvals for Venclexta in treating relapsed or refractory and first-li... | AbbVie still has other late-stage studies of veliparib in progress as a treatment for non-squamous non-small cell lung cancer, BRCA1/2 breast cancer, and ovarian cancer. AbbVie (NYSE: ABBV) continues to reel from its announcement last week of very disappointing results for rovalpituzumab tesirine (Rova-T) as a third-li... | AbbVie still has other late-stage studies of veliparib in progress as a treatment for non-squamous non-small cell lung cancer, BRCA1/2 breast cancer, and ovarian cancer. AbbVie should have results from two late-stage studies of upadacitinib in treating psoriatic arthritis next year. AbbVie (NYSE: ABBV) continues to ree... | Risks great and small In my view, elagolix is the least risky asset in AbbVie's pipeline. Next on the risk scale, in my opinion, are AbbVie's two immunology candidates, upadacitinib and risankizumab. AbbVie (NYSE: ABBV) continues to reel from its announcement last week of very disappointing results for rovalpituzumab t... |
25,588 | 2018-03-26 00:00:00 UTC | The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer | ABBV | https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-abbvie-jj-heron-therapeutics-roche-and-pfizer-2018-03 | null | null | For Immediate Release
Chicago, IL - March 26, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include AbbVieABBV , J&JJNJ , Heron T... | Stocks recently featured in the blog include AbbVieABBV , J&JJNJ , Heron TherapeuticsHRTX , RocheRHHBY and PfizerPFE . Here are highlights from Friday's Analyst Blog: Pharma Stock Roundup: ABBV, JNJ, HRTX and More Discouraging results from a phase II study evaluating AbbVie's promising cancer candidate rovalpituzumab t... | Recap of the Week's Most Important Stories AbbVie's Rova-T Falls Short in Key Lung Cancer Study: AbbVie's promising cancer candidate, rovalpituzumab tesirine or Rova-T fell short of expectations in a phase II TRINITY study evaluating it in third-line or later small cell lung cancer (SCLC). Click to get this free report... | Recap of the Week's Most Important Stories AbbVie's Rova-T Falls Short in Key Lung Cancer Study: AbbVie's promising cancer candidate, rovalpituzumab tesirine or Rova-T fell short of expectations in a phase II TRINITY study evaluating it in third-line or later small cell lung cancer (SCLC). Click to get this free report... | Stocks recently featured in the blog include AbbVieABBV , J&JJNJ , Heron TherapeuticsHRTX , RocheRHHBY and PfizerPFE . Here are highlights from Friday's Analyst Blog: Pharma Stock Roundup: ABBV, JNJ, HRTX and More Discouraging results from a phase II study evaluating AbbVie's promising cancer candidate rovalpituzumab t... |
25,589 | 2018-03-26 00:00:00 UTC | Monday's ETF with Unusual Volume: XMX | ABBV | https://www.nasdaq.com/articles/mondays-etf-unusual-volume-xmx-2018-03-26 | null | null | The WisdomTree Global ex-Mexico Equity Fund ETF ( XMX ) is seeing unusually high volume in afternoon trading Monday, with over 1.1 million shares traded versus three month average volume of about 50,000. Shares of XMX were down about 0.3% on the day.
Components of that ETF with the highest volume on Monday were Faceboo... | Microsoft ( MSFT ) is the component faring the best Monday, higher by about 6% on the day, while Abbvie ( ABBV ) is lagging other components of the WisdomTree Global ex-Mexico Equity Fund ETF, trading lower by about 5.2%. The WisdomTree Global ex-Mexico Equity Fund ETF ( XMX ) is seeing unusually high volume in afterno... | Microsoft ( MSFT ) is the component faring the best Monday, higher by about 6% on the day, while Abbvie ( ABBV ) is lagging other components of the WisdomTree Global ex-Mexico Equity Fund ETF, trading lower by about 5.2%. The WisdomTree Global ex-Mexico Equity Fund ETF ( XMX ) is seeing unusually high volume in afterno... | Microsoft ( MSFT ) is the component faring the best Monday, higher by about 6% on the day, while Abbvie ( ABBV ) is lagging other components of the WisdomTree Global ex-Mexico Equity Fund ETF, trading lower by about 5.2%. The WisdomTree Global ex-Mexico Equity Fund ETF ( XMX ) is seeing unusually high volume in afterno... | Microsoft ( MSFT ) is the component faring the best Monday, higher by about 6% on the day, while Abbvie ( ABBV ) is lagging other components of the WisdomTree Global ex-Mexico Equity Fund ETF, trading lower by about 5.2%. The WisdomTree Global ex-Mexico Equity Fund ETF ( XMX ) is seeing unusually high volume in afterno... |
25,590 | 2018-03-23 00:00:00 UTC | 5 Dividend Aristocrats Where Analysts See Capital Gains | ABBV | https://www.nasdaq.com/articles/5-dividend-aristocrats-where-analysts-see-capital-gains-2018-03-23 | null | null | To become a "Dividend Aristocrat," a dividend paying company must accomplish an incredible feat: consistently increase shareholder dividends every year for at least 20 consecutive years. Companies with this kind of track record tend to attract a lot of investor attention - and furthermore, "tracking" funds that follow ... | With all of this demand for shares, dividend growth stocks can sometimes become "fully priced," where there isn't much upside to analyst targets. To ballpark that total return potential, we have added the current yield to the analyst target price upside, in order to arrive at the 12-month total return potential: Anothe... | The recent share price, average analyst 12-month target price, and percentage upside to reach the analyst target are presented. The average 12-month analyst targets are only targets for the share price however, and each of these stocks are expected to pay dividends during that holding period - so the expected total ret... | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The average ... | But we here at ETF Channel have looked through the underlying holdings of the SPDR S&P Dividend ETF (which tracks the S&P High Yield Dividend Aristocrats Index), and found these five dividend growth stocks that actually still have fairly substantial upside to the average analyst target price 12 months out. The recent s... |
25,591 | 2018-03-23 00:00:00 UTC | Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus | ABBV | https://www.nasdaq.com/articles/cancer-space-roundup%3A-nvs-tasigna-sgens-adcetris-label-expansions-in-focus-2018-03-23 | null | null | The cancer space saw label expansion of two major drugs this week. Seattle Genetics, Inc.'s SGEN , Adcetris label was expanded to include treatment naive patients with advanced Hodgkin lymphoma (cHL). Novartis' NVS Tasigna received approval for use in pediatric patients, one year of age or older.
Meanwhile, the FDA gra... | However, AbbVie ABBV announced disappointing results from a mid-stage study evaluating its lung cancer candidate, Rovalpituzumab Tesirine (Rova-T). Roche Holding AG Price Roche Holding AG Price | Roche Holding AG Quote AbbVie's Rova-T Fails in Phase II Study: AbbVie shares crashed on Thursday, following the announcemen... | Roche Holding AG Price Roche Holding AG Price | Roche Holding AG Quote AbbVie's Rova-T Fails in Phase II Study: AbbVie shares crashed on Thursday, following the announcement of disappointing results from a pivotal phase II study evaluating Rova-T in third-line or later small cell lung cancer. Click to get this free rep... | Roche Holding AG Price Roche Holding AG Price | Roche Holding AG Quote AbbVie's Rova-T Fails in Phase II Study: AbbVie shares crashed on Thursday, following the announcement of disappointing results from a pivotal phase II study evaluating Rova-T in third-line or later small cell lung cancer. Click to get this free rep... | Roche Holding AG Price Roche Holding AG Price | Roche Holding AG Quote AbbVie's Rova-T Fails in Phase II Study: AbbVie shares crashed on Thursday, following the announcement of disappointing results from a pivotal phase II study evaluating Rova-T in third-line or later small cell lung cancer. However, AbbVie ABBV annou... |
25,592 | 2018-03-23 00:00:00 UTC | Is AbbVie Still a Buy After Its Rova-T Setback? | ABBV | https://www.nasdaq.com/articles/abbvie-still-buy-after-its-rova-t-setback-2018-03-23 | null | null | AbbVie (NYSE: ABBV) enjoyed a nice streak of mainly positive news over the last six months. From striking a deal to hold off U.S. biosimilar competition for Humira to positive clinical updates to solid quarterly results, the big pharma was on a roll. That ended earlier this month when AbbVie and partner Biogen announce... | On Thursday, AbbVie announced results from a phase 2 study evaluating rovalpituzumab tesirine (Rova-T) as a third-line treatment for relapsed/refractory small cell lung cancer (SCLC). To add insult to injury, AbbVie included an asterisk to the results that noted that the data represented 74% of the patients participati... | On Thursday, AbbVie announced results from a phase 2 study evaluating rovalpituzumab tesirine (Rova-T) as a third-line treatment for relapsed/refractory small cell lung cancer (SCLC). At the J.P. Morgan Healthcare Conference earlier this year, AbbVie CEO Rick Gonzalez stated that the company projects $35 billion in ris... | On Thursday, AbbVie announced results from a phase 2 study evaluating rovalpituzumab tesirine (Rova-T) as a third-line treatment for relapsed/refractory small cell lung cancer (SCLC). Even if we cut out potential sales for Rova-T altogether and shaved another $5 billion of AbbVie's 2025 non-Humira risk-adjusted revenue... | On Thursday, AbbVie announced results from a phase 2 study evaluating rovalpituzumab tesirine (Rova-T) as a third-line treatment for relapsed/refractory small cell lung cancer (SCLC). AbbVie's announcement on Thursday was definitely very bad news for the company. AbbVie (NYSE: ABBV) enjoyed a nice streak of mainly posi... |
25,593 | 2018-03-23 00:00:00 UTC | AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome | ABBV | https://www.nasdaq.com/articles/abbvie-abbv-stock-falls-on-weak-lung-cancer-study-outcome-2018-03-23 | null | null | AbbVie, Inc.ABBV announced disappointing results from a pivotal phase II study, evaluating its promising cancer candidate rovalpituzumab tesirine or Rova-T in third-line or later small cell lung cancer (SCLC).
AbbVie said it will not seek accelerated approval of Rova-T in the third-line SCLC setting after consulting wi... | AbbVie is also conducting studies on another cancer drug, Venclyxto/Venclexta to expand the label to address the broader relapsed/refractory chronic lymphocytic leukemia (CLL) patient population, expand into earlier lines of therapy, and broaden into other hematologic malignancies like multiple myeloma and AML. AbbVie,... | AbbVie said it will not seek accelerated approval of Rova-T in the third-line SCLC setting after consulting with the FDA. Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report Teva Pharmaceuti... | AbbVie, Inc.ABBV announced disappointing results from a pivotal phase II study, evaluating its promising cancer candidate rovalpituzumab tesirine or Rova-T in third-line or later small cell lung cancer (SCLC). Click to get this free report Roche Holding AG (RHHBY): Free Stock Analysis Report Johnson & Johnson (JNJ): Fr... | AbbVie said it will not seek accelerated approval of Rova-T in the third-line SCLC setting after consulting with the FDA. AbbVie, Inc.ABBV announced disappointing results from a pivotal phase II study, evaluating its promising cancer candidate rovalpituzumab tesirine or Rova-T in third-line or later small cell lung can... |
25,594 | 2018-03-22 00:00:00 UTC | Why Is AbbVie (ABBV) Stock Crashing Today? | ABBV | https://www.nasdaq.com/articles/why-abbvie-abbv-stock-crashing-today-2018-03-22 | null | null | Shares of pharmaceutical behemoth AbbVie Inc. ABBV dropped more than 11% in early morning trading Thursday after the company's Rova-T program reported disappointing mid-stage results, forcing the drugmaker to abandon plans to seek accelerated approval for the treatment.
AbbVie was hopeful that its Rova-T, or rovalpituz... | Shares of pharmaceutical behemoth AbbVie Inc. ABBV dropped more than 11% in early morning trading Thursday after the company's Rova-T program reported disappointing mid-stage results, forcing the drugmaker to abandon plans to seek accelerated approval for the treatment. AbbVie was hopeful that its Rova-T, or rovalpituz... | Nevertheless, AbbVie said that it does still believe the drug has potential in small cell lung cancer and other cancers with the DLL3 protein. Click to get this free report AbbVie Inc. (ABBV): Free Stock Analysis Report To read this article on Zacks.com click here. Shares of pharmaceutical behemoth AbbVie Inc. ABBV dro... | Shares of pharmaceutical behemoth AbbVie Inc. ABBV dropped more than 11% in early morning trading Thursday after the company's Rova-T program reported disappointing mid-stage results, forcing the drugmaker to abandon plans to seek accelerated approval for the treatment. AbbVie was hopeful that its Rova-T, or rovalpituz... | Nevertheless, AbbVie said that it does still believe the drug has potential in small cell lung cancer and other cancers with the DLL3 protein. Shares of pharmaceutical behemoth AbbVie Inc. ABBV dropped more than 11% in early morning trading Thursday after the company's Rova-T program reported disappointing mid-stage re... |
25,595 | 2018-03-22 00:00:00 UTC | RSI Alert: AbbVie (ABBV) Now Oversold | ABBV | https://www.nasdaq.com/articles/rsi-alert-abbvie-abbv-now-oversold-2018-03-22 | null | null | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 26.5, after changing hands as low as $97.36 per share. A bullish investor could look at ABBV's 26.5 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and... | The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in its 52 week range is $63.1153 per share, with $125.86 as the 52 week high point - that compares with a last trade of $97.06. In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold te... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 26.5, after changing hands as low as $97.36 per share. The chart below shows the one year performance of ABBV shares: Looking at the chart above, ABBV's low point in its 52 week range is $63.1153 per s... | In trading on Thursday, shares of AbbVie Inc (Symbol: ABBV) entered into oversold territory, hitting an RSI reading of 26.5, after changing hands as low as $97.36 per share. According to the ETF Finder at ETF Channel, ABBV makes up 6.95% of the First Trust Nasdaq Pharmaceuticals ETF (Symbol: FTXH) which is trading lowe... |
25,596 | 2018-03-22 00:00:00 UTC | AbbVie Inc Stock Dives on Lung Cancer Drug Results | ABBV | https://www.nasdaq.com/articles/abbvie-inc-stock-dives-lung-cancer-drug-results-2018-03-22 | null | null | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
AbbVie Inc (NYSE: ABBV ) stock was falling hard today following results from a Phase 2 study of lung cancer drug Rovalpituzumab Tesirine (Rova-T).
Source: Black Stripe via Wikimedia (Modified)
Rova-T is a drug that is designed to target cancer-stem cell-ass... | 7 High-Quality Dividends for 2018 and Beyond "Although the results from the study were not what we hoped for, we look forward to receiving data from the ongoing Phase 3 studies in the first- and second-line settings and remain committed to developing Rova-T for the treatment of patients with small cell lung cancer," Mi... | 7 High-Quality Dividends for 2018 and Beyond "Although the results from the study were not what we hoped for, we look forward to receiving data from the ongoing Phase 3 studies in the first- and second-line settings and remain committed to developing Rova-T for the treatment of patients with small cell lung cancer," Mi... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) stock was falling hard today following results from a Phase 2 study of lung cancer drug Rovalpituzumab Tesirine (Rova-T). 7 High-Quality Dividends for 2018 and Beyond "Although the results from the study were not what we hoped for, ... | InvestorPlace - Stock Market News, Stock Advice & Trading Tips AbbVie Inc (NYSE: ABBV ) stock was falling hard today following results from a Phase 2 study of lung cancer drug Rovalpituzumab Tesirine (Rova-T). The poor results from the Phase 2 study means that AbbVie Inc is changing its plans for Rova-T. 7 High-Quality... |
25,597 | 2018-03-22 00:00:00 UTC | S&P 500 Movers: ABBV, CMG | ABBV | https://www.nasdaq.com/articles/sp-500-movers-abbv-cmg-2018-03-22 | null | null | In early trading on Thursday, shares of Chipotle Mexican Grill topped the list of the day's best performing components of the S&P 500 index, trading up 2.8%. Year to date, Chipotle Mexican Grill registers a 18.9% gain.
And the worst performing S&P 500 component thus far on the day is AbbVie, trading down 10.6%. AbbVie ... | And the worst performing S&P 500 component thus far on the day is AbbVie, trading down 10.6%. AbbVie is showing a gain of 3.9% looking at the year to date performance. VIDEO: S&P 500 Movers: ABBV, CMG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those o... | VIDEO: S&P 500 Movers: ABBV, CMG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing S&P 500 component thus far on the day is AbbVie, trading down 10.6%. AbbVie is showing a gain of 3.9% looking at the year to dat... | VIDEO: S&P 500 Movers: ABBV, CMG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. And the worst performing S&P 500 component thus far on the day is AbbVie, trading down 10.6%. AbbVie is showing a gain of 3.9% looking at the year to dat... | And the worst performing S&P 500 component thus far on the day is AbbVie, trading down 10.6%. VIDEO: S&P 500 Movers: ABBV, CMG The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. AbbVie is showing a gain of 3.9% looking at the year to dat... |
25,598 | 2018-03-22 00:00:00 UTC | This Explains Why AbbVie Is Falling Today | ABBV | https://www.nasdaq.com/articles/explains-why-abbvie-falling-today-2018-03-22 | null | null | What happened
After the biotech giant's disappointing update on an important experimental cancer drug, shares of AbbVie (NYSE: ABBV) fell as much as 12% in early morning trading on Thursday. Shares were down 11% as of 10:35 a.m. EDT.
So what
The drug in question is called rovalpituzumab tesirine, which goes by the nick... | What happened After the biotech giant's disappointing update on an important experimental cancer drug, shares of AbbVie (NYSE: ABBV) fell as much as 12% in early morning trading on Thursday. So what The drug in question is called rovalpituzumab tesirine, which goes by the nickname Rova-T. AbbVie shared a little bit of ... | So what The drug in question is called rovalpituzumab tesirine, which goes by the nickname Rova-T. AbbVie shared a little bit of data from a phase 2 trial today that was studying Rova-T as a third-line treatment for relapsed/refractory small-cell lung cancer. What happened After the biotech giant's disappointing update... | So what The drug in question is called rovalpituzumab tesirine, which goes by the nickname Rova-T. AbbVie shared a little bit of data from a phase 2 trial today that was studying Rova-T as a third-line treatment for relapsed/refractory small-cell lung cancer. AbbVie plans to share much more data with investors from thi... | So what The drug in question is called rovalpituzumab tesirine, which goes by the nickname Rova-T. AbbVie shared a little bit of data from a phase 2 trial today that was studying Rova-T as a third-line treatment for relapsed/refractory small-cell lung cancer. AbbVie plans to share much more data with investors from thi... |
25,599 | 2018-03-22 00:00:00 UTC | Is It Game Over for AbbVie's Promising Cancer Drug? | ABBV | https://www.nasdaq.com/articles/it-game-over-abbvies-promising-cancer-drug-2018-03-22 | null | null | AbbVie Inc. (NYSE: ABBV) is racing against time. Patents protecting its best-selling drug, Humira, expire in the EU later this year, and management is scrambling to develop new drugs that can make up for any lost sales when biosimilars launch in the U.S. in 2023. The company's plans to diversify its revenue away from H... | Given AbbVie's still got a few years before Humira's competition emerges, it's got multiple shots on goal, and it's got plenty of cash flowing in from its current products, buying it on sale could be smart. AbbVie Inc. (NYSE: ABBV) is racing against time. And what does it mean for AbbVie's future ? | AbbVie Inc. (NYSE: ABBV) is racing against time. And what does it mean for AbbVie's future ? Up until now, AbbVie believed that big need could allow it to file for an accelerated approval of Rova-T in small-cell lung cancer patients who've received at least two previous treatment regimens, including at least one platin... | After discussing Rova-T's midstage trial results with the Food and Drug Administration (FDA), AbbVie is abandoning plans to file for an early approval. AbbVie Inc. (NYSE: ABBV) is racing against time. And what does it mean for AbbVie's future ? | Management plans to file for risankizumab's approval by the end of the second quarter, and if it gets the green light for psoriasis and other indications, AbbVie thinks it can win be a $5-billion-per-year drug someday. AbbVie Inc. (NYSE: ABBV) is racing against time. And what does it mean for AbbVie's future ? |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.